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VACCINATION AND IMMUNOLOGICAL MEMORY 
by Gianfranco Di Genova 
 
Human subjects maintain long-term immunological memory against infective 
organisms but the mechanism is unclear. CD4
+ T helper memory cells (Thmem) are 
pivotal in controlling humoral and cellular responses, therefore their longevity and 
response to vaccination are critical for maintenance of protective immunity. To probe 
the dynamics of the Thmem response to antigenic challenge, we investigated subjects 
following a booster injection with tetanus toxoid (TT). Expansion of TT-specific 
Thmem cells, and cytokine production, showed complex kinetics. Strikingly, parallel 
expansion and cytokine production occurred in pre-existing Thmem cells specific for 
two other common antigens, Purified Protein Derivative of tuberculin (PPD), and 
Candida albicans (C.alb). Bystander expansion occurred in Thmem but not in Thnaive 
cells. Antibody production against TT peaked ~2 weeks post-vaccination and 
gradually declined. However, pre-existing antibody against the other antigens did not 
change. It appears that, although all Thmem cells are readily stimulated to expand, 
antibody responses are controlled by antigen availability. These human findings 
which relate to the maintenance of memory and have consequences for assessments of 
specific T-cell responses to vaccination, have been further investigated in a mouse 
model.   
   
A transgenic model (OT-II) where CD4
+  T cells express a TCR specific for an 
ovalbumin peptide (peptide 323-339, OVAp) was used first to ask the question as to   
whether naïve or antigen-activated T cells were influenced in a bystander manner 
during a secondary immune response directed against a protein antigen that was 
unrelated to their cognate one.  For this, carboxyfluorescein diacetate succunimidyl 
ester (CFSE)-labeled OT-II cells were adoptively transferred, either as naïve or   4
following  in vitro activation with OVAp, into C57/BL6 wild type recipient mice 
which were immune to TT. Recipient mice were then challenged with TT antigen and 
susceptibility of OT-II cells to bystander activation and proliferation was tested.   
Naïve T cells were found not to be influenced, but antigen-activated cells were 
responsive and underwent further activation and bystander proliferation, with 
accompanying phenotypic changes. Interestingly bystander proliferation appeared to 
be proportional to the strength of TT-specific cellular immune response.  
 
The second question was whether the bystander influence on activated T cells was 
also evident during a primary immune response to TT. To address this question, 
antigen-activated OT-II cells and control naïve cells were adoptively transferred into 
wild type naïve recipient mice and their activation and proliferation was assessed after 
challenge with TT. In this case no bystander activation or proliferation of OT-II cells 
was observed.  
 
These results underline the susceptibility to bystander activation and proliferation as a 
unique feature of antigen-activated OT-II cells as opposed to naïve OT-II cells. They 
mirror those obtained in our study on human subjects and add formal proof of 
bystander proliferation occurring in vivo. Furthermore this well defined mouse model 
paves the way for further investigations aimed at addressing the mechanisms 
responsible for the observed phenomenon. 
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Chapter 1. Bystander activation of CD4
+ memory T cells following 
protein vaccination in human healthy volunteers 
 
1.1  Introduction 
 
1.1.1  Innate and adaptive immunity 
 
The immune system has the primary function of defending the body against microbial 
pathogens. Early lines of defence are provided by a combination of cellular and 
biochemical mechanisms already in place even before infection. They constitute the 
so called innate immunity and consist of (1) physical and chemical barriers, such as 
epithelia and antimicrobial substances produced at epithelial surfaces; (2) circulating 
effector cells, such as phagocytic cells (e.g. neutrophils, macrophages) and natural 
killer (NK) cells; (3) circulating effector proteins, such as members of the 
complement system and so-called “natural” antibodies; (4) proteins, such as 
cytokines, that regulate and coordinate many activities of the cells of innate immunity. 
The components of innate immunity are there to prevent infection or, when infection 
occurs, to react rapidly (within hours) and eliminate the microbes. Specificity of 
action is assured by the recognition of structures that are shared by classes of 
microbes (‘molecular patterns’) and are not present on mammalian cells, and are often 
essential for survival of the microbes.  
 
Together with the defence mechanisms of the innate immunity, there are immune 
responses that develop later (within days after infection) and are characterized by 
some key features: (1) an exquisite specificity, directed against pathogen-specific 
antigens, and which makes it possible to distinguish among different, even closely 
related, microbes and molecules; (2) an enormous diversity with the potential to 
recognize up to 10
9 distinct antigenic determinants; and (3) the unique ability to 
‘remember’ and respond more effectively to repeated exposures to the same microbe, 
also known as immunological memory. This form of immunity develops in response 
to infection and adapts specifically to the infection and for these reasons is known as 
‘adaptive’ or ‘specific’ immunity, or sometimes as ‘acquired’ immunity, to underline 
that it is acquired by experience. Adaptive immunity comprises two arms,   18
traditionally referred to as humoral immunity and cell-mediated or cellular immunity. 
The principal orchestrators of humoral and cell-mediated immunity are B and T 
lymphocytes respectively, and their products. These subpopulations of lymphocytes 
differ in the way they recognize antigens and in their functions. B lymphocytes use a 
surface-expressed B cell receptor (BCR) to recognize extracellular antigens. They 
then differentiate into antibody-producing cells or plasma cells. The secreted 
antibodies directly bind to and neutralize microbes and microbial toxins by blocking 
their binding to cellular receptors, or they coat (opsonize) invading pathogens making 
them visible targets for innate immunity.  
 
T lymphocytes do not recognize free extracellular pathogens. Instead, they use their T 
cell receptor (TCR) to recognize (microbial and non-microbial) antigen-derived 
peptides associated and presented by major histocompatibility complex (MHC) 
molecules on the surface of infected cells or on the surface of specialized antigen 
presenting cell (APC). Among mature T lymphocytes two well defined subsets exist, 
which are easily identifiable by the surface expression of either the CD4 or the CD8 
molecule. CD4 and CD8 are co-receptors that bind to non-polymorphic regions of 
MHC molecules and contribute to signal transduction at the time of antigen 
recognition 
7. CD4
+ and CD8
+ T cells recognize peptide presented by class II and 
class I MHC molecules, respectively. Upon antigen recognition and activation, T 
lymphocytes differentiate into functionally distinct populations of effectors such as 
cytotoxic T lymphocytes (CTLs) which can directly destroy infected cells, or helper T 
(Th) cells which secrete cytokines that regulate proliferation and differentiation of T 
and B cells or activation of other effector cells such as macrophages, and finally 
regulatory T cells which mainly function to inhibit immune responses. 
 
While innate and adaptive immunity have traditionally been regarded as two distinct 
and temporally separated arms of the immune system, and the efficacy of one was 
thought to be independent of the other, there is now accumulating evidence to suggest 
that components of the innate and adaptive immunity interact and influence each other 
to assure an optimal outcome for the immune response. A relevant example is given 
by the bidirectional interactions between NK cells, a major effector cell population of 
the innate immune system, and dendritic cells (DCs), a class of highly specialized   19
APCs, which, as will be explained later in this introduction, are key initiators and 
regulators of the adaptive immune response 
8. 
 
1.1.2  Immunological memory 
 
As discussed earlier, a key feature of the adaptive immune response is the ability to 
remember the first encounter with a pathogen, so that the severity of a second 
infection by the same pathogen is dramatically reduced. This phenomenon, of 
experiencing a milder form of a disease or being protected from a disease if 
previously exposed to it, is commonly known. People who have suffered from a 
disease like measles and mumps as children, if they survive the primary infection, are 
unlikely to succumb on re-exposure in their adult life. This phenomenon has been 
observed many times. In fact in 430 B.C. the Greek historian Thucydides, describing 
the plague of Athens, first reported that “The same man was never attacked twice” 
9. 
More recent studies on resistance to infections in individuals belonging to isolated 
human populations subjected to two consecutive outbreaks of the same infectious 
disease occurring decades apart have provided further scientific evidence for it 
10. 
From these studies two important conclusions can be drawn: first that protective 
immunity and therefore immune memory can be long-lived (between 40 and 75 years 
in these studies), and second that re-exposure to the pathogen is not necessary. 
Although this second principle, that is the maintenance of immunological memory by 
what we now call antigen-independent mechanisms, is still debated by the scientific 
community, recent elegant studies on long-term immunity to vaccinia virus in 
individuals who have received the smallpox vaccine which contains a live vaccinia 
virus 
11, seem to offer further and robust evidence in its favour, and will be discussed 
in more detail later in this introduction. 
 
Immunological memory and the principles behind it, also form the basis for 
vaccination. The origin of vaccination, defined as a deliberate attempt to protect 
against a severe disease by a direct exposure to a mild form of it, dates back to the 
ancient practice of variolation, popular in China and India as early as in the 10
th 
century A.D. Healthy people were infected with dried pox material taken from 
someone recovering from smallpox, in the attempt of inducing a mild infection 
capable of protecting them from more virulent disease. This practice carried high   20
morbidity and although introduced also in Europe in the 18
th century, it was soon 
discontinued 
10. With the pioneering work of Edward Jenner the era of modern 
vaccination and immunology begins. In 1798 he described how protection against 
smallpox could be obtained by vaccinating people with a related milder virus, 
cowpox, therefore without contracting the actual disease. The success of Jenner’s 
approach is proven by the fact that in 1980 the World Health Organization declared 
smallpox eradicated worldwide and modern vaccines against common bacterial and 
viral diseases have reduced morbidity and mortality and improved the quality of life 
of millions of people.  
 
What is the cellular and molecular basis of immunological memory and how is this 
immunological memory maintained, sometimes for the lifetime of an individual? 
These questions have fascinated immunologists for a long time and continue to do so. 
The answers are crucial to our basic understanding of the immune system and 
consequently to any conscious planning of intervention aimed at raising the immune 
system against pathogens. Parts of the answers are already known, others are 
beginning to be elucidated.  
 
Humoral and cell-mediated immunity, both contribute to immunological memory, 
although their relative contributions to protective immunity can vary with the 
infection. Components of humoral immunity which contribute to immunological 
memory comprise pathogen-specific pre-existing neutralizing antibodies, memory B 
cells and long-lived plasma cells (LLPC). Components of cell-mediated immunity 
include pathogen-specific CD4
+ and CD8
+ memory T cells. Pre-existing neutralizing 
antibodies persisting in the serum constitute the first line of defence against re-
infection. Memory B cells are populations of cells clonally expanded during the first 
encounter with the pathogen located mainly in secondary lymphoid organs where they 
are present at higher frequencies as compared to naïve B cells with the same antigen 
specificities. They do not actively secrete antibodies but possess a high affinity BCR 
and are able to mount a rapid recall response. In fact, upon re-encounter with the 
specific antigen, they quickly divide to replenish their pool and some of them 
differentiate into antibody-secreting plasma cells. LLPC are terminally differentiated 
effector cells which reside in the bone marrow and constitutively produce antibody in 
the absence of antigenic stimulation. In fact, they express minimal levels of BCR or   21
do not express it at all, and cannot be stimulated to divide or to boost the rate of 
antibody production. The ability to constitutively exert an effector function, in this 
case antibody production, independently of antigenic stimulation is a unique feature 
of plasma cells, and there is no cell type equivalent to the plasma cell in the T-cell 
compartment, where antigen is  the main regulator of effector functions 
12. Similarly 
to memory B cells, memory CD4
+ and CD8
+ T cells are pathogen-specific cells 
clonally expanded during the primary response and enhanced in functions 
12,13. CD4
+ 
T cells can also provide help for antibody production and support for the generation 
and maintenance of CD8
+ memory T cells 
14, therefore their role in the context of a 
pathogen-specific immune response is strategic.   
 
How these populations of memory cells are maintained for long periods of time is still 
not clear but it is crucial to understand, especially in view of developing effective 
vaccines which require both arms of the immune response to be engaged and to 
remain active for a long time. In this introduction attention is focused mainly on 
memory T cells and among them on CD4
+ memory T cells. Their generation and 
maintenance together with their increasingly appreciated phenotypic and functional 
complex heterogeneity will be discussed. 
 
1.1.3  Phases of adaptive immune responses 
 
In the process leading to the generation of memory, T cells pass through three distinct 
kinetic stages: an initial ‘expansion’ phase, followed by a ‘contraction’ phase, which 
finally leads to a ‘memory’ phase 
15. The first stage begins when antigen-specific 
naïve T cells, normally present at low frequency in naïve hosts, following encounter 
with cognate antigen, are activated and undergo clonal expansion. Recognition of 
antigen can only take place in the specialized environment of secondary lymphoid 
organs where naïve CD4
+ and CD8
+ T cells recognize antigen-loaded MHC class II 
and I complexes respectively, on the surface of ‘professional’ APC, such as DCs, via 
their highly specific cell-surface TCR. DCs play a key role in this initial phase of 
naïve T cell activation, and also, as we shall see, in ‘shaping’ the following immune 
response.  
   22
A classical model proposes that DCs exist in two basic functional states 
16: an 
immature and a mature state. Immature DCs are characterized by very good antigen 
capture and antigen processing abilities, but by relatively poor immunogenicity. When 
located in peripheral organs and mucosal surfaces, they continually sample the 
environment for foreign antigens. They can ‘sense’ pathogens by recognizing 
pathogen-associated molecular patterns (PAMPs) via pathogen recognition receptors 
(PRRs) such as Toll-like receptors (TLRs), and signaling through TLRs influences 
many crucial aspects of DC biology. After antigen has been captured and processed, a 
maturation program begins, characterized by increased immunogenicity and decreased 
antigen acquisition and antigen processing ability 
16. Maturation can be accompanied 
by migration to secondary lymphoid tissues where ‘mature’ DCs are able to 
efficiently stimulate naïve T cells due to an increased surface expression of MHC 
class I and class II and costimulatory molecules, such as B7-1 and B7-2 (CD80 and 
CD86), which interact with their specific ligand CD28 on the T cell surface. When the 
combined intracellular biochemical signals provided by the TCR/MHC-peptide 
interaction (signal 1) and the costimulatory pathways (signal 2) reach a defined 
activation threshold, a program of activation, proliferation and differentiation begins 
for the naïve T cells. In the absence of signal 2 naïve T cells can become anergic, and 
this might lead to tolerance rather than immunity 
7.  
 
In Figure 1.1, the induction of the adaptive immune response is summarized.  The key 
initial event is represented by the bidirectional interaction between a mature DC and a 
naïve CD4
+ T cell. The DC, after capturing and processing the antigen, displays 
antigen-derived peptides loaded on MHC class II molecules on the surface and, due to 
the high levels of costimulatory molecules, provides the CD4
+ T cell with all the 
signals it needs to become activated. The CD4
+ T cell, following activation, expresses 
the CD40L (CD154) molecule on the surface, which binds to CD40 on the surface of 
the DC and stimulates the DC. As a consequence, even higher levels of MHC 
molecule expression are induced on the DC. According to one prevailing model 
17,18, 
this DC is now ‘licensed’ to activate a CD8
+ T cell which shares the same antigen 
specificity with the CD4
+ T cell. After initial activation by DCs, CD4
+ T cells can also 
interact with B lymphocytes that have previously captured native antigen by means of 
their BCR, and have internalized it and processed it. These B cells now act themselves 
as APCs and present antigen-derived peptides complexed with MHC class II   23
molecules to CD4
+ T cell which share the same antigen specificity. Again a cross talk 
takes place and reciprocal activation occurs and leads to the proliferation and 
differentiation of the B cell. Cytokines produced by the CD4
+ T cells further drive this 
process. 
 
 
 
Figure 1.1 (Adapted from 
1). The induction of the adaptive immune response   24
Clonally expanded naïve T cells differentiate into effector T cells. Well characterized 
effector cells are Th cells among the CD4
+, and CTLs among the CD8
+ T cells. Based 
on the pattern of cytokines secreted, CD4
+ Th cells can be divided into functional 
subsets known as Th1, which produce the signature cytokine interferon (IFN)-γ, and 
Th2 cells, which typically produce interleukin 4 (IL-4), IL-5 and IL-13, but also other 
cytokines. Th1 cells are essential for protection against a range of intracellular 
infections (and tumours). Th2-like cytokines (e.g. IL-4) promote isotype switching in 
B cells to generate high affinity antibodies and can play a role in protection against 
extracellular infections, such as nematode parasitic infections 
7. More recently, a 
novel subset of CD4
+ T helper cells has been characterized and named Th-17 based on 
the cytokine produced, IL-17 
19. These are pro-inflammatory cells involved in several 
autoimmune disorders. 
  
Among the CD4
+ T cells, there are also several subsets of cells with regulatory 
functions, capable of controlling effector T cell responses. Examples of T regulatory 
(Treg) cells are the well characterized ‘naturally occurring’ CD4
+ CD25
+ Tregs 
(nTreg), the IL-10-secreting T regulatory type 1 (Tr1) cells, the induced Treg (iTreg) 
and the TH3 cells 
20. While nTreg develop directly from thymic precursors during the 
normal process of T cell maturation, the remaining subsets seem to differentiate from 
peripheral T helper precursors through the actions of different cytokines, and at least 
for Tr1 and TH3 cells, in response to antigen
20,21.  
 
Therefore, after antigenic stimulation, naïve CD4
+ T cells proliferate and differentiate 
into various effector subsets characterized by the production of distinct cytokines and 
by their distinct (sometime opposite) effector functions. This process of differentiation  
of CD4
+ T cell lineages from a common precursor is regulated by the cytokine-milieu 
present early during the immune response and by activation of specific transcription 
factors 
2 as summarized in Figure 1.2.   25
 
Figure 1.2 (from 
2). Differentiation  of CD4
+ T cell lineages 
 
For example, IL-12 produced by activated macrophages and DCs, and IFN-γ, in 
conjunction with signal transducer and activator of transcription 4 (STAT 4) and T-
bet, promote differentiation of Th1 effectors, while IL-4 and the transcription factors 
STAT 6 and GATA-3 favor induction of Th2 cells. The differentiation of Th-17 from 
naïve precursors depends on the presence of cytokines such as transforming growth 
factor (TGF-β) and IL-6 and requires blockade of Th1 and Th2 differentiation. 
Another cytokine, IL-23 is essential for their expansion and survival 
19. Once an 
immune response develops along one pathway, it becomes increasingly polarized in 
that direction because the cytokines produced by each subset (typically IFN-γ by Th1 
cells and IL-4 by Th2 cells) tend to further promote differentiation of that subset and 
at the same time they inhibit the differentiation along the alternative pathway.  
 
How can T cell responses be directed towards the most appropriate effector type in 
response to a given pathogen? Increasing evidence suggests that DCs play a pivotal 
role as an interface between the ‘pathogen world’ and the immune system 
22. Distinct 
pathogens activate phenotypically and functionally distinct subsets of effector DCs   26
(directly, via interaction of particular PRRs with PAMPS, and/or indirectly, through 
various inflammation-associated tissue factors released in response to pathogen 
invasion), which in turn, can polarize the adaptive immune response in order to 
produce the most appropriate effectors (Th1 or Th2 cells, or in some instances, 
regulatory T cells) 
16,22.  
 
Similarities and differences exist between CD4
+ and CD8
+ T cells in their 
requirements for efficient effector formation. Although for both a transient exposure 
to antigen is sufficient to induce an antigen-independent program of proliferation and 
differentiation, naïve CD8
+ T cells seem to require a shorter time of antigen 
stimulation and, in response to that, they also divide sooner and at a faster rate, as 
compared to naïve CD4
+ T cells, suggesting a higher proliferative potential 
23. While 
naïve CD8
+ T cells more readily develop into cytolytic and/or cytokine-producing 
effector cells, the differentiation of naïve CD4
+ T cells into terminally committed Th1 
or Th2 cells is subject to more extensive regulatory mechanisms as described above. 
The response of naïve CD8
+ T cells is also less dependent on costimulatory signals, as 
shown in mouse models of viral or bacterial infections 
15. This suggests that either 
CD4
+ and CD8
+ T cells differ in their activation threshold (lower for CD8
+ T cells), or 
that factors extrinsic to the T cell (levels and type of activation signals) help CD8
+ T 
cells meet the activation threshold for proliferation and differentiation more rapidly 
15. 
A more efficient in vivo antigen presentation due to the ubiquitous expression of 
MHC class I molecules as compared to class II, could be one of those factors.  
 
A reduced expression of lymph node-homing receptors, such as CC-chemokine 
receptor 7 (CCR7), a homing molecule required for T cells to cross high endothelial 
venules (HEV) and enter the lymph node from the bloodstream, and L-selectin 
(CD62L) together with an increased expression of chemokine receptors such as CCR5 
and CCR2, allow migration of effector T cells to inflamed tissues where they can 
exert their primary task, which is clearance of the antigen 
15. They do this by various 
means, either by directly recognizing and killing infected cells, as CTL mainly do, or 
by producing inflammatory cytokines such as IFN-γ and tumour necrosis factor-α 
(TNF-α) which in turn can activate macrophages and enhance their microbicidal 
activity. These effector functions are displayed immediately by effector T cells,   27
thanks to their lower activation threshold and less stringent requirements for co-
stimulation. 
 
After the antigen is cleared the majority of effector T cells die by apoptosis during 
what it is known as the ‘death’ phase or contraction phase of the immune response. 
For CD8
+ effector T cells the contraction is quite remarkable. In various infection 
models, it accounts for the loss of up to 90-95 % of the effector cells, and this death 
rate seems to be independent of the magnitude of the initial expansion 
24. Information 
on the kinetics of CD4
+ T cell responses is more limited. However in one study on the 
response to smallpox vaccination in human volunteers, CD4
+ T cell responses showed 
less contraction and better persistence when compared to CD8
+ T cell responses, both 
after primary immunization and also after a boosting injection 
25.   
 
The extent of cell death during the contraction phase is influenced by the common γ 
chain family of cytokines (cytokines such as IL-2, IL-4, IL-7 and IL-15, which share 
the subunit γ of the cytokine receptor) 
26, members of the TNF receptor superfamily 
(such as CD27, OX40, 4-1BB and CD154) 
26,27 and effector cell molecules (such as 
perforin and IFN-γ) 
23,26. Effector T cell apoptosis can be the consequence of 
activation-induced cell death (AICD), which occurs when expanded T cells are re-
stimulated via TCR in the absence of appropriate co-stimulatory signals. It can also 
result from the lack of appropriate survival signals (e.g. cytokine deprivation). In this 
case T cell death does not require re-stimulation of the TCR and it is known as 
activated cell autonomous death (ACAD) 
28. While AICD seems to be important for 
elimination of chronically activated and potentially autoreactive T cells, ACAD seems 
to play a major role during the contraction phase of the immune response 
29.The 
pathways involved in effector T cell death appear to be activated by either external 
signals, such as the interaction of Fas expressed on the surface of activated T cells 
with its ligand FasL, via a caspase-dependent pathway, or by intrinsic signals via a 
pathway that leads to mitochondrial dysfunction. In this case the balance between pro-
apoptotic and anti-apoptotic members of the Bcl-2 family is critical 
30.  
 
The contraction phase is thought to be important for preserving immune system 
homeostasis, leaving space for T cell responses against new infections, and in   28
preventing possible immunopathological consequences often associated with an 
excessive effector T cell response. The surviving cells enter the third phase of the 
immune response and tend to persist for long periods of time as “memory” cells.  
 
 
1.1.4  The development of T cell memory 
 
Most of the information available on the development of memory T cells derives from 
mouse studies, in most cases using TCR transgenic T cells. The use of TCR 
transgenic animals makes it possible to obtain sufficient numbers of T cells of a given 
specificity which can be easily identified and monitored in their in vitro and/or in vivo 
response to the specific antigen usually by clonotypic antibodies directed against the 
transgenic TCR. Although these studies have been instrumental in deciphering some 
intriguing aspects of naïve, effector and memory T cell behaviour, there are 
limitations associated with the use of TCR transgenic T cells which cannot be 
ignored, such as for instance the high and usually non-physiological number of TCR 
transgenic T cells used. Also there is a dangerous tendency to extrapolate results 
obtained from mouse studies obtained in a particular setting (e.g. a particular model of 
viral or bacterial infection), and to draw general conclusions or rules which are then 
applied to humans.  However, some data are available from studies in humans and in 
many cases they are revealing. An example is the identification of subsets of memory 
T cells with distinct phenotypic and functional properties initially described in 
humans 
31, and then confirmed in mice. These studies have brought attention to the 
complexity of T cell memory and will be described in one of the following sections. 
In general a balance should be found, where mouse and human immunology 
complement each other with the communal aim of establishing robust and durable 
immunological principles.  
 
 
1.1.5  Pathways to T cell memory  
 
A central question in T cell memory development is the lineage relationship between 
naïve, effector and memory T cells. How early during an adaptive immune response is 
the commitment to memory T cell differentiation decided and what regulates it? The   29
answer is still unclear. Comparisons with B cells can be useful. After naïve B cells 
have been  activated by antigen in the presence of CD4 T cell help (see above), they 
continue along one of two divergent pathways: they either differentiate into short-
lived plasma cells (PC) (effectors) or they initiate a germinal center (GC) reaction. 
Somatic hypermutation, affinity maturation and selection take place in the GC and 
result in the generation of high affinity memory B cells (MBCs). MBCs face a similar 
choice when re-stimulated by antigen. In fact they divide rapidly and can differentiate 
into either PCs or give rise to more MBCs. The commitment of B cells to differentiate 
into PCs or to keep their B-cell ‘identity’ is finely regulated by the balance of 
transcription factors such as B-lymphocyte-induced maturation protein-1 (Blimp-1) 
and X-box binding protein 1 (XBP-1) and interferon regulatory factor 4 (IRF 4), 
which favour plasma cell differentiation, and those such as the paired box protein 5 
(PAX5) and microphthalmia-associated transcription factor (MITF), which in turn 
help maintaining memory B cell identity 
12. Therefore for B cells, it is clearly a 
divergent pathway that leads to memory development, and the decision on which way 
to proceed, is taken very early by the differentiating B cell. It would also be difficult 
to envisage an alternative model, considering the irreversible changes B cells are 
subjected to when they differentiate into either effectors (loss of BCR) or memory 
cells (somatic hypermutation).  
 
For naïve T cells the differentiation into effector cells is not accompanied by such 
radical changes. With some exceptions, effector T cells do not permanently lose TCR 
expression and TCR do not somatically mutate, therefore the B cell model of 
differentiation cannot be simply extrapolated to T cells. Historically memory T cells 
have been described as a minority of T cells which survive the contraction phase of 
the immune response. This implies that memory T cells derive from the expanded 
effector T cells, or in other words that a linear differentiation pathway exists leading 
from naïve to effector to memory. For CD8
+ T cells evidence to support this model 
comes from studies using TCR transgenic CD8
+ effector T cells generated either in 
vitro following stimulation with cognate peptide 
32, or in vivo following infection with  
lymphocytic choriomeningitis virus (LCMV) 
33, and adoptively transferred into naïve 
syngeneic recipients, where they gradually give rise to a population of long-lived 
memory T cells. These findings would suggest that precursors of CD8 memory T cells 
exist within the effector population.  A similar linear differentiation pathway has also   30
been proposed for CD4
+ memory T cells 
34. Swain SL and colleagues (1994) were the 
first to demonstrate the emergence of CD4
+ memory T cells from a population of 
effector cells antigen-activated in vitro under polarizing (Th1 or Th2) conditions and 
transferred into naïve recipients
35. Interestingly the polarized cytokine producing 
profile of the effector cells was maintained by the memory population, offering 
further evidence for their direct link.  
 
If memory T cells derive from effectors, what regulates the effector → memory 
transition? This is still unclear. Attempts have been made to identify precursors within 
the effector population destined to become memory cells, looking, for instance, at 
differential expression of cytokine receptors. In a mouse model of LCMV infection, it 
has been proposed that among the CD8
+ effector T cells at peak of the response, 
expression of IL-7 receptor α-chain (IL-7Rα) identifies precursors that give rise to 
long-lived memory cells 
36. In this model, increased expression of IL-7Rα in the 
effector cells correlates with increased survival signals and reduced apoptosis 
36. 
Interestingly the degree of contraction and efficiency of CD8 T cell memory 
establishment seem to be linked to inflammatory events, and specifically to IFN-γ 
production, taking place very early during an infection as shown in a model of 
Listeria monocytogenes infection 
37. When bacterial load and inflammation (IFN-γ 
production) are decreased by pre-treating mice with antibiotics, an increased fraction 
of antigen-specific CD8
+ T cells express IL-7Rα at the peak of expansion and the 
development of functional antigen-specific memory CD8
+ T cells occurs in the 
absence of contraction 
15.  
 
A critical role in the establishment of CD8
+ T cell memory is performed by CD4
+ T 
cells. Several groups, using different experimental systems, have provided clear 
evidence in support of the idea that while CD8
+ effector T cells can be generated in 
the absence of CD4
+ T cell help, fully functional CD8
+ memory T cells  can be 
induced only when CD4
+ T cells are present during the priming phase of the CD8
+ T 
cell response 
38-41. 
 
For CD4
+ T cells, factors, acting early during T cell activation, such as cytokines and 
costimulators, can contribute to memory formation. Signals provided by IL-2 and   31
CD28 during priming confer a long-lasting survival advantage in primed T cells, 
contributing to the persistence of a memory population 
42. IL-2 and CD28 signals do 
not act by promoting T-cell division and expansion, but by inducing survival proteins 
(e.g. anti-apoptotic molecules such as Bcl-2) and expression of receptors for survival 
factors such as IL-7 
43. The role of IL-7 in the maintenance of CD4
+ memory T cells is 
well known and it will be discussed in more detail in one of the following sections. A 
lack of CD40L signals during priming did not seem to have an impact on subsequent 
memory development 
42. Other costimulatory molecules have been considered for 
their contribution to CD4
+ T cell memory, among them OX40. OX40 (CD134) is a 
member of the TNFR family and is induced on T cells after antigenic stimulation.  It 
has been shown that OX40 promotes CD4
+ memory development by regulating 
primary clonal expansion 
44 and by promoting expression of anti-apoptotic molecules 
Bcl-xL and Bcl-2 
45, and therefore by enhancing the overall survival and functionality 
of T cells that will persist as memory cells.  
 
Differentiation into effectors is not always a requirement for memory development. 
Liu Y and colleagues demonstrated that activation of distinct costimulatory molecules 
induces either effector or memory CTLs 
46. Also, particular vaccine-formulations can 
induce priming of memory but not effector CD8
+ T cells 
47, although the induced 
memory cells are non-protective against re-infections.  
 
For CD4
+ T cells a branched differentiation model has been proposed as an alternative 
to the classic linear differentiation pathway 
3. The idea is that CD4
+ memory T cells 
can be generated from activated precursors in diverse differentiation states, including 
from cells which have not yet acquired effector functions 
48 . A schematic diagram of 
these two alternative models is shown in Figure 1.3.    32
 
Figure 1.3 (from 
3). Prevailing models for the differentiation of CD4
+ memory T cells 
 
If the differentiation into effectors is not a pre-requisite step for T cell memory 
development, how early during the transition from naïve to memory, does the 
divergent pathway branch off the naïve → effector pathway? Moulton VR and 
colleagues indicate that CD4
+ TCR transgenic naïve T cells stimulated with specific 
antigen in vitro for just one day, with no evident acquired effector functions, can 
develop into a stable population of memory cells when transferred into antigen-free 
mouse hosts 
48. In a recent breakthrough investigation Chang JT and colleagues have 
gone further, to show that the fate of a T cell is determined as early as during the very 
first division that follows antigen stimulation 
49. In fact, upon activation, naïve
 T cells 
undergo asymmetric cell division, with asymmetric redistribution of fate-determining 
cues (e.g. signaling molecules, phenotypic markers and effector gene products) among 
daughter cells. Data show that as a consequence, one daughter cell can become the 
precursor of the effector T cell progeny and the other can become the precursor of the 
memory T cell progeny. Interestingly, the daughter cell precursor of the memory T 
cell progeny shows greater expression of IL-7Rα mRNA (see above). These findings 
bring T cells and B cells closer in their developmental behaviour.  Future research 
efforts might re-focus on the very early stages of naïve T cell activation, especially on   33
factors intrinsic to the cell and we might see rapid progress in our understanding of 
the pathway/s leading to T cell memory.    
 
1.1.6  Phenotypic and functional characteristics of naïve, effector and memory 
T cells 
 
Upon re-exposure to cognate antigen, memory T cells can mediate enhanced immune 
responses, which in association with antibody responses efficiently control secondary 
infections and therefore contribute to protective immunity. A direct comparison of 
naïve and memory T cells which share the same antigen specificity can explain the 
heightened recall response by memory T cells. In fact as a consequence of the 
expansion phase occurring during the primary immune response, memory T cells are 
present at a higher precursor frequency; they also maintain a feature typical of effector 
T cells, that is, the rapid display of effector functions at low activation thresholds.  
 
For CD8
+ T cells, the rapid production of cytokines such as IFN-γ and cytotoxic 
molecules, such as perforin and granzyme B, can be achieved due to the constitutive 
expression of their respective genes which in naïve cells are not expressed. This leads 
to the presence of high levels of messenger RNA transcripts which, following 
encounter with antigen, can be promptly translated 
15. When compared to naïve cells, 
CD4
+ memory T cell responses to recall antigens are characterized by faster kinetics 
of cytokine secretion (effector cytokines IL-4, IL-5 and IFN-γ), cell division, and 
proliferation which occur at lower doses of antigen and are less dependent on 
costimulation by B7 molecules and are independent of costimulation by CD40 
50,51. 
 
The transition from one stage to another in the development of memory T cells is 
accompanied by changes in the expression of phenotypic markers and there has 
always been an attempt to associate a particular phenotype with defined functional 
properties. In man, expression of CD45 isoforms distinguishes naïve (CD45RA
+ 
CD45RO
-) from memory T cells (CD45RA
- CD45RO
+) 
52, although this is not 
absolute since the expression of CD45RA has been demonstrated in subsets of 
antigen-experienced CD8
+ and CD4
+ T cells 
53.  In mice, the search for definite 
phenotypic markers of memory T cells has been more problematic. High expression   34
of CD44 (a cell adhesion receptor whose principal ligand, hyaluronate, is a common 
component of extracellular matrices, and whose expression changes upon activation 
and differentiation of T cells) has widely been used as a marker of both CD4
+ and 
CD8
+ memory T cells, although it is also expressed on activated T cells. Less useful 
has been CD62L, because of its heterogeneous expression. For mouse CD4
+ T cells, it 
would appear that a consensus has now been reached, and the differential expression 
of three markers, CD25 (the α subunit of the IL-2 receptor complex, IL-2Rα), CD127 
(IL-7Rα) and CD44, together with cell size, allow distinction of naïve, effector and 
memory T cells 
6. Some distinctive properties of mouse naïve, effector and memory 
CD4
+ T cells are summarized in Table 1.1 
 
 
Table 1.1 (from 
6). Distinctive properties of mouse naïve, effector and memory CD4
+ T cells 
 
The co-stimulatory molecules CD27 and CD28, and the lymph node homing receptor 
CCR7 are expressed on naïve T cells and tend to be down-regulated in antigen-
experienced effector T cells in relation to their less stringent requirements for 
additional costimulatory signals and their altered migratory capacity respectively. 
Down-regulation of CD27 in particular is irreversible. Based on the combined 
expression of these markers, a post-thymic linear development pathway has been 
proposed for CD8
+ T cells in man 
53. According to this, four main phenotypic subsets 
can be identified, starting from naïve (CD28
+ CD27
+ CCR7
+) T cells, progressing 
through early (CD28
+CD27
+CCR7
(+) →( -)), intermediate (CD28
- CD27
+ CCR7
-), and 
late (CD28
-CD27
-CCR7
-) differentiation stages for antigen-experienced T cells. The 
sequential down-regulation of CCR7, CD28 and CD27 is accompanied by up-
regulation of cytotoxic factors. CD4
+ T cells go through similar phenotypic and 
functional changes with loss of expression of CD27 and CD28 and CCR7, gain of 
cytolytic functions and reduced capacity to produce IL-2 and to proliferate. 
Interestingly, the loss of CD27 precedes that of CD28 and the acquisition of lytic   35
capacity which begins early after priming of naïve CD8
+ T cells, occurs in CD4
+ T 
cells only when they reach a highly differentiated stage. Although the in vivo 
significance of each of these phenotypic subsets remains to be fully understood, one 
view is to see late differentiation stage T cells as cells approaching senescence, as 
suggested by their reduced proliferative capacity  and shortened telomere length 
53. It 
still remains to be clarified what drives progressive differentiation of T cells and what 
is the potential of each subset in conferring protective immunity.  
 
1.1.7  T-cell differentiation in persistent human virus infections 
 
Phenotypic studies of virus-specific CD8
+ T cells in infections characterized by an 
acute phase followed by a persistent chronic phase, such those induced by human 
immunodeficiency virus (HIV), Epstein-Barr virus (EBV), Cytomegalovirus (CMV), 
Hepatitis B virus (HBV) and Hepatitis C virus (HCV), have revealed interesting clues. 
Despite a similar phenotype of activated antigen-experienced cells, shown by virus-
specific CD8 T cells during the acute phase of each of those infections, the degree of 
differentiation of CD8 T cells during the chronic phase seems to be virus-specific, 
with, for instance, HCV-specific CD8
+ T cells showing an early differentiation 
phenotype (CD27
+CD28
+), whereas CMV-specific CD8
+ T cells having a late 
differentiation phenotype (CD27
-CD28
-).  Early intermediate and intermediate 
phenotypes characterize hepatitis B-specific or HIV-specific CD8
+ T cells 
respectively 
53.  Furthermore, in EBV infection the pattern varies according to 
whether T cells recognize lytic or latent antigens. HIV and CMV chronic infections 
are also characterized by accumulation of oligoclonal antigen-experienced population 
with a restricted TCR usage, a phenomenon that leads to a reduced ability to respond 
to emerging viral variants or to other common and opportunistic pathogens.  
 
The factors likely to  influence the differentiation of virus-specific CD8+ T cells 
include the following: the antigen-load and the degree of antigen re-encounter 
54; 
persistence, anatomical location and presentation of antigen. Variable levels of 
activation and costimulation in the end are responsible for different levels of 
differentiation observed.  
   36
The relationship between the degree of differentiation and protective immunity is still 
controversial, although accumulating data suggest that protective immunity may 
better conferred by early differentiated T cells which maintain high proliferative 
potential 
53. When differentiation is far advanced, CD8
+ T cells become gradually 
impaired in effector functions, including cytokine production, cytolysis and 
proliferation, and this functional impairment has been called ‘exhaustion’. Exhaustion 
ultimately leads to death of the CD8
+ T cells 
55. Whether exhaustion is a pre-step 
inevitably leading to death or is in some way reversible, is not clear. Interestingly, in a 
mouse model of LCMV infection, it has been shown that in vivo blockade of the 
interaction between the inhibitory protein programmed death 1 (PD-1), which is 
selectively up-regulated by the exhausted T cells, and its ligand PD-L1, can restore 
functionality in virus-specific CD8
+ T cells 
56. These results, although obtained in a 
mouse model, are promising and may pave the way for the development of therapies 
to improve T cell responses in patients with chronic viral infections.  
 
1.1.8  Central memory and effector memory T cells 
 
Recently, the expression of CD45RA and CCR7 together with that of another lymph 
node homing receptor CD62L has also been used to define two functionally distinct 
subsets of memory T cells, central and effector memory T cells, TCM and TEM 
respectively 
31. TCM home to secondary lymphoid tissue, have little or no effector 
functions, but can rapidly proliferate and differentiate into effector cells upon 
antigenic stimulation. TEM cells home to peripheral tissue (e.g. sites of inflammation), 
can promptly produce effector cytokines, such as IFN-γ, following antigenic 
stimulation, but have limited proliferative potential 
31. In the context of a secondary 
memory response, these two subsets of memory T cells would carry out distinct roles. 
While TEM can offer immediate protection against invading pathogens in peripheral 
tissues, TCM can offer long-term protection, being able to generate new waves of 
effector cells in antigen-draining lymph nodes.  
 
A model has been proposed 
4 (Figure 1.4) according to which TCM and TEM originate 
as intermediates in the process of differentiation from naïve to effector T cells. This 
process is controlled by the strength of stimulation received by TCR engagement and   37
cytokines.  At increasing strength of stimulation activated T cells acquire the 
capability of responding to homeostatic cytokines; they acquire anti-apoptotic 
molecules, effector functions and tissue-homing receptors. Meanwhile they lose the 
capacity to produce IL-2 and to proliferate as well as lymph node homing receptors 
(CCR7 and CD62L). T cells receiving the optimal amount of stimulation survive as 
TCM and TEM, whereas T cells receiving a too weak or too high stimulation die.  
 
 
 
Figure 1.4 (from 
4). A model of progressive T cell differentiation driven by signal strength 
 
Although the TCM and TEM model has provided us with a logical key for understanding 
the complexity of immune memory, proposing elegant correlations between 
phenotype, anatomic localization and distinct functions, and assigning distinct roles to 
subsets of memory T cells in the logic of an immune response, nevertheless recent 
data have highlighted many controversies on the differential function and role of TCM 
and TEM types and on their lineage relationship 
57. For instance, immediate effector 
functions can be exerted by human CMV- or EBV-specific CCR7+ CD8+ T cells 
58, 
and in a mouse model of viral infection, LCMV-specific CCR7+ and CCR7- memory 
T cells do not differ in immediate effector cell function 
59,60. The role of TCM and TEM 
in mediating protection is also a matter of controversy. While in a secondary response   38
to LCMV TCM maintained high expansion capacities and were responsible for 
protection 
60, in a Sendai virus infection opposite results were observed, with TEM 
showing potential to expand and to exert protective functions 
61. Also, the distinction 
between effector cells and effector memory cells based on phenotypic and functional 
characterization can become difficult when complete clearance of antigen is not fully 
guaranteed. In fact in theses cases an effector-like profile might reflect recent antigen 
re-stimulation rather than a resting memory subtype 
19.  
 
The lineage relationship between TCM and TEM has also been questioned and 
alternative models for the development of the two subsets have been proposed 
62. One 
of them describes a ‘linear differentiation’ pathway according to which CD8 TEM 
develop directly from the pool of effector T cells generated from naïve T cells in 
response to antigen. The conversion of effector T cells to TEM occurs after the primary 
infection is resolved. Interestingly, during the memory phase, and in the absence of 
antigen, TEM gradually  de-differentiate into TCM  
60. So in this model and in contrast to 
what originally thought, TEM convert to TCM.  
 
Some of the observed discrepancies can be explained by different criteria that various 
authors choose in defining the two subsets of memory T cells, either based on 
phenotype or anatomic location 
57. They can also reflect the heterogeneity that each of 
the two subsets itself can have 
63 or differences existing among the models of 
infection chosen.  
 
Although the TCM and TEM model is open to criticism and has led to some rather 
simplistic categorizations, overall it has had the merit of highlighting the complex 
heterogeneity of memory T cell populations 
19.    
 
 
1.1.9  Maintenance of immunological memory  
 
Although observations on resistance to infection have indicated  longevity of memory 
64, the mechanism of maintenance has been unclear. Immunological memory can be 
maintained by several antigen-dependent mechanisms which include re-activation of 
latent/chronic infections or periodic re-exposures to a pathogen. Both are obvious and   39
effective ways to maintain high levels of immunity as shown by epidemiological 
studies carried out in areas where a given disease is endemic 
10. Immunological 
memory can also be maintained in the absence of repeated antigenic boosting events. 
Evidence in support of an antigen-independent maintenance of immunological 
memory will be discussed in the following sections together with the possible 
mechanisms responsible for it. 
 
1.1.10  Immunological memory following smallpox vaccination 
 
Elegant studies on immunity against vaccinia virus  in human subjects vaccinated 
with smallpox vaccine,  revealed that, although no exposure to smallpox (vaccinia) 
virus can have occurred for many years,  survival of specific CD4
+ and CD8
+ T cells 
is evident decades after vaccination 
65-67.  Similarly, plateau levels of functional 
memory B cells persist for >50 years 
65. In these studies, T cell responses declined 
slowly over time, with a half life of 8-12 years for CD4
+ and 8-15 years for CD8
+ 
vaccinia-specific T cells, nevertheless they were still detectable up to 75 years after 
vaccination 
66.  Interestingly, CD4 and CD8 T cell responses seemed to be regulated 
independently over time and a direct comparison of CD4 and CD8 responses in 
individual vaccinees, revealed that in a significant proportion of cases there was a 
preferential loss of CD8
+ T cells while CD4
+ T cells were maintained long-term 
66. 
These findings were confirmed in an independent study by Amara et al.
25 who showed 
how the vaccinia-specific CD8
+ T cells displayed a higher contraction between peak 
effector and memory phases than CD4
+ T cells. Importantly those individuals who 
selectively lost CD8
+ T cells after primary immunization could still generate a strong 
CD8 T cell response after a booster vaccination with smallpox vaccine, demonstrating 
that their ability to mount a vaccinia-specific CD8 T cell response was intact.  
Since vaccinia virus is believed neither to persist nor to become latent after the acute 
phase of infection, these studies support the idea that other antigen-independent 
mechanisms may contribute to the maintenance of immunological memory.  
Strong evidence in support of this concept comes also from several mouse models 
showing persistence of CD4
+ and CD8
+ memory T cells in antigen-free MHC class II-
, and class I-deficient mice, respectively 
68,69.  
   40
1.1.11  Kinetics of naïve and memory T cells 
 
The long term persistence of memory T cells at a population level can result either 
from ongoing proliferation, from increased survival or from both. A comparison of 
the kinetics of naïve and memory T cell populations in mouse 
70 and man 
71, shows 
increased turnover of memory T cells compared with naïve T cells. In man, shortening 
of telomeres at each cell cycle limits the number of divisions the cell can go through, 
and this is thought to be an important control mechanism of cell growth, that finally 
leads to a non-dividing state known as replicative senescence. A higher division rate 
makes memory T cells more subject to telomere erosion and in fact CD45R0
+ 
memory T cells have shorter telomeres compared to CD45RA
+ naïve T cells 
72. The 
activity of the enzyme telomerase tends to compensate for the loss of telomeres; in 
fact ectopic expression of the human telomerase reverse transcriptase (hTERT) gene 
can prevent telomere erosion and extend the life span of human T cells 
73,74. 
Endogenous hTERT expression is up-regulated following activation, but T cells tend 
to lose the ability to up-regulate hTERT upon long-term culture 
73. Interestingly, 
although hTERT expression is up-regulated in both activated naïve and memory T 
cells freshly isolated from human subjects, the expression levels are lower in memory 
T cells, and this probably reflects the greater replicative history of memory T cells 
73.  
 
Overall these data suggest that long-term persistence of populations of memory T 
cells can only be assured by a combination of signals able to promote proliferation 
and some degree of telomerase activity. Furthermore, due to the limits imposed by 
replicative senescence, there must also be signals able to improve survival. The nature 
of these signals is not entirely understood, but a major role seems to be played by 
cytokines, as it will be described in the following sections.  
 
1.1.12  Role of cytokines: in vitro studies 
 
How an effective population of memory T cells can be maintained over the lifetime of 
the host in the apparent absence of antigen is a major question. One suggested route is 
via non-specific stimulation by cytokines, and this has been shown to occur in human 
Thmem cells in vitro 
63,75,76.   
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When highly purified naïve (CD45RA
+) and memory (CD45R0
+) resting human 
CD4
+ T cells are cultured in vitro with a combination of IL-2, tumor necrosis factor α 
(TNFα) and IL-6, in the absence of TCR engagement, they express activation 
markers, enter cell cycle and proliferate 
75. The cytokine-activated CD45R0
+ memory 
population can also exert effector functions (IFN-γ and IL-4 synthesis) and provide T 
cell help for antibody production by B cells 
75. The authors speculated that this 
antigen-independent pathway of T cell activation could play an important role in vivo, 
in boosting an antigen-specific immune response and at the same time in maintaining 
the peripheral pool of memory T cells.  In fact, resting T cells at sites of an antigen-
specific response could be activated by cytokines produced by antigen-specific T cells 
and antigen presenting cells. They would proliferate and secrete cytokines that in turn 
could further amplify the specific immune response. This model may perhaps explain 
the high proportion (40-80%) of activated T cells among the lymphocytes infiltrating 
the liver of patients with chronic viral hepatitis, despite the fact that only a small 
percentage of them are virus-specific 
77. In fact those T cells might have been 
activated in a bystander fashion. Similarly, high numbers of proliferating CD8
+ T cells 
have been reported in mouse models of viral infections such as influenza, and among 
the proliferating cells only a small percentage was virus-specific 
78. 
 
There is a group of cytokines whose members bind to multimeric receptors that share 
a common γ chain (γc). Among them, IL-2, IL-15, and IL-7 are critical for regulating 
lymphoid homeostasis 
79. Low-level signals provided by IL-7 and MHC molecules 
promote prolonged survival of naïve T cells without inducing proliferation 
80. By 
contrast, IL-7 and IL-15 induce background proliferation in CD8
+ memory T cells and 
also promote their survival. CD4
+ T cells rely mainly on signals provided by IL-7 for 
their slow turn-over and survival 
80. As already discussed in a previous paragraph, 
memory T cells  do not require contact with peptide-MHC complexes for their long-
term survival 
68,69.  
 
The ability of human CD4
+ naïve T cells, memory T cells, and TCM and TEM subsets 
of memory T cells to respond to IL-7 and IL-15 was tested in vitro 
81. When cultured 
with IL-7 and IL-15, naïve CD4+ T cells failed to respond, while memory T cells 
proliferated strongly. Addition of autologous dendritic cells (DCs) or supernatants   42
derived from cultures of LPS-activated DCs, enabled all naïve T cells to respond to 
the cytokine combination and enhanced the response of memory T cells. Among the 
memory subsets, TEM cells proliferated extensively to IL-7 and IL-15, while TCM cells 
were less responsive and could respond only when DC-derived cytokines, such as 
TNF-α, IL-6 and IL-10 were added to the culture. Interestingly, the boosting effect of 
DC-derived cytokines on IL-7 and IL-15 induced proliferation was linked to their 
ability of up-regulating the IL-15Rβ and the γc chains on target cells 
81.  
 
1.1.13  A role for cytokines in the bystander proliferation of memory T cells in 
vivo 
 
Early studies by Sprent J and colleagues established that a significant bystander 
proliferation of T cells takes place during viral infections in mice 
82. Proliferation of 
CD8
+ T cells was more pronounced than proliferation of CD4
+ T cells, and the 
majority of the bystander proliferating CD8
+ T cells showed a memory-like phenotype 
(CD44
high) 
82. They could then demonstrate that activation of the innate immune 
system was involved. In fact injection of type I interferon (IFN I) or IFN I–inducing 
agents such as lipopolysaccharide (LPS) and the synthetic double strand RNA 
polyinosinic-polycytidylic acid (Poly I:C) could mimic the effect of viral infections in 
inducing bystander proliferation of  CD8
+ memory T cells
82,83. The effect of IFN-I 
was not direct, but was instead mediated by production of secondary cytokines, 
among which IL-15 appeared to be a good candidate. IL-15 was later shown to be 
produced by, and to activate dendritic cells in response to type I IFN, double-stranded 
RNA, or LPS 
84. Most importantly, IL-15 could induce strong and selective 
stimulation of memory-phenotype CD8
+CD44
high (but not CD4
+CD44
high) T cells in 
vivo in an antigen-independent manner 
85. The high and selective sensitivity of CD8
+ 
CD44
high memory T cells to the mitogenic effects of IL-15 could be possibly 
explained by the high expression of IL-2/IL-15Rβ (one of the components of the IL-
15 receptor) on the surface of this subset of T cells as opposed to other subsets, 
including CD4
+CD44
high cells 
85.  
 
The range of infection-induced cytokines able to cause bystander proliferation of 
memory T cells in vivo remains to be elucidated. Among other cytokines tested, IL-  43
12, IL-18, and IFN-γ were found to exert effects similar to those induced by type I 
IFN, although all by an IFN-γ-dependent pathway 
86. 
 
In vivo, activation of NKT cells (a subset of CD1d-restricted T cells expressing a 
biased TCR repertoire and markers common to the NK cell lineage) by the synthetic 
ligand α-galactosylceramide (α-GalCer), and activation of T cells by a bacterial 
superantigen, also lead to extensive proliferation of both CD4
+ and CD8
+ memory 
(CD44
high) T cells which can be IFN-αβ-independent but IFN-γ- and IL-12-dependent 
87.  
 
Overall these studies, mainly focused on CD8
+ memory T cells, demonstrate that 
bystander or antigen-independent proliferation of memory T cells can be induced in 
vivo by several mechanisms which involve the activation of different cell types in 
response to viruses or bacterial products, and is driven by cytokines released during 
such activation. This bystander activation/proliferation of memory T cells could 
contribute to their long-term maintenance.   
 
1.1.14  Bystander activation/proliferation of memory CD4
+ T cells in human 
subjects 
 
One way to study antigen-independent bystander activation of memory T cells in vivo 
in human subjects is to evaluate the impact of infection or vaccination on resident 
memory cells with antigen specificities unrelated to the infectious agent or to the 
vaccine. Although there are few published studies, there have been some intriguing 
observations which point to bystander effects.  In one study of vaccination with TT, 
limiting dilution analysis of proliferating cells revealed the expected increase in the 
frequency of TT-specific cells, but this was accompanied by a modest but significant 
increase in the frequency of herpes simplex virus-specific cells
88 . Similarly, after a 
TT boost, PBMNC from three healthy donors showed an increased proliferative 
response to PPD as compared to pre-boost responses
89 .   
  
A part from these studies, not specifically designed to study bystander activation of 
memory T cells following protein vaccination, to our knowledge no other study has   44
systematically investigated the impact of conventional protein vaccination on the 
kinetics of vaccine-specific and bystander CD4
+ memory T cells.   
 
1.1.15  The maintenance of B cell memory 
 
In terms of B cells, maintenance of antibody levels can be partially explained by new 
estimates of the survival of plasma cells, which in mice can persist throughout life 
90. 
Non-dividing plasma cells are thought to occupy survival niches in bone marrow and 
spleen 
91. The bone marrow provides only a limited number of survival niches for 
long-lived plasma cells. Recent investigations 
92,93 suggest that during a secondary 
immune response to tetanus vaccination, while newly produced tetanus-specific 
plasma blasts are released from secondary lymphoid organs into the blood and are 
then chemo-attracted to the bone marrow, long-lived plasma cells resident in the bone 
marrow and producing antibodies not specific for tetanus are mobilised and are 
detectable in the blood. These observations are suggestive of an active competition 
between newly released vaccine-induced plasma blasts and resident plasma cells for 
the limited number of survival niches available in the bone marrow. This could 
represent a mechanism by which humoral immunity adapts to the antigenic 
environment, by gradually lowering the titer of antibodies specific to antigens not 
seen for long time and by creating space for immunity against newly encountered 
antigens.  
 
In long-lived human subjects, it is unlikely that long-lived plasma cells can be the 
only source of persisting antibody, and continuous maturation of memory B cells may 
be required.   Memory B cells can certainly persist without antigen stimulation 
94, and 
could be stimulated to differentiate via cross-reacting antigen, or possibly via an 
antigen-independent pathway 
95.  
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1.2   Aims of the study 
 
1.2.1  To verify whether, in healthy human subjects, bystander 
activation/proliferation of CD4
+ memory T cells occurs during an immune 
response against a protein antigen. 
 
Our plan is to conduct a detailed analysis of the kinetics of cellular immune responses 
to TT recall vaccination in humans and, in parallel, to analyze responses against two 
un-related antigens, PPD and C. alb. Most individuals show various degrees of pre-
existing immunity to these three antigens, either because they have been vaccinated 
(against TT and Bacille Calmette-Guérin (BCG) for PPD) or because they have been 
naturally exposed to them (C. alb). Therefore this represents an ideal setting for 
studying how perturbation of a population of memory T cells (in this case vaccine-
induced), can impact on the behavior of surrounding memory T cells with unrelated 
antigen specificities.  
 
We shall focus our attention on Thmem because of their pivotal role in controlling 
humoral and cellular responses, therefore their longevity and response to vaccination 
are critical for maintenance of protective immunity. There is also relatively scarce 
information on the kinetics of CD4 T cell responses to conventional vaccination in 
humans. Gathering this information would help us in the interpretation of data derived 
from on-going clinical studies on cellular immune responses in patients with 
hematological malignancies who are receiving novel DNA fusion vaccines developed 
in our laboratory, which contain a tetanus toxin-derived sequence (fragment C) as 
immune-enhancer.  
 
1.2.2  To verify whether bystander activation can occur in the B-cell 
compartment  
 
Our plan is to analyze the kinetics of serum antibody responses again each of the three 
recall antigens: TT, PPD and C. alb.    46
1.3  Materials and methods 
 
1.3.1  Vaccination and sample collection 
 
After obtaining ethical approval for the study from the Independent Review Board 
(IRB) and informed consent, twelve healthy adults (8 males, 4 females), (31 – 44y), 
received a single dose of TT vaccine i.m. (Adsorbed Tetanus Vaccine BP, Aventis 
Pasteur MSD). All subjects had been vaccinated against TT but had not received a 
boost during the previous five years. All subjects had also received conventional 
vaccination with BCG. Blood samples were taken before vaccination (week 0) and 
then at weeks 1, according to availability, and 2. Subsequent samples were taken at 4-
week intervals up to week 20. Serum was isolated by spinning clotted blood for 20 
minutes at 2100 rpm. It was then aliquoted and  stored at –20
oC. Peripheral blood 
mononuclear cells (PBMNC) were isolated by centrifugation of heparinized blood on 
a Lymphoprep
TM density gradient. Briefly, each 10 ml of blood were gently layered 
onto 10 ml of Lymphoprep in 25ml universal vials, and spun at 2100 rpm for 20 
minutes without brake. PBMNC recovered at the interface using a plastic Pasteur 
pipette were washed twice in RPMI 1640 medium (Invitrogen) (2 x 1650 rpm for 7 
minutes), resuspended in 50% human AB serum (Sigma), 40% RPMI 1640 and 10% 
DMSO, and frozen at -80 
oC. The following day they were moved into liquid-N2 for 
long-term storage. The viability of defrosted cells was always very good, overall 90.2 
+/- 2.6 %. In one case (subject 13) PBMNC were isolated from blood and soon after 
used for immuno-assays. 
 
1.3.2  Antigens  
 
Antigens were: TT (not adsorbed) and Candida albicans whole extract, cytoplasmic 
protein (C. alb) (National Institute for Biological Standards and Control, NIBSC, 
UK); PPD prepared from human strains of Mycobacterium tuberculosis (Evans 
Vaccines Limited, UK); normal human immunoglobulin for intravenous 
administration (Vigam Liquid 5g, Bio Products Laboratory, UK) (control 1, Ctrl1) 
and an IgA paraprotein purified from the serum of a patient with multiple myeloma 
(control 2, Ctrl 2). These endotoxin-free proteins were selected as controls with no   47
pre-existing immunity. In cellular assays TT was used at 1µg/ml and all the remaining 
antigens at 10µg/ml.  
 
1.3.3  Proliferative responses  
 
Cryopreserved PBMNC were thawed in pre-warmed RPMI-1640, containing 1-2 % 
human AB serum (Sigma, Cat N
o H-4522) and washed for 10 minutes at 300g. Cells 
were counted and the number of viable cells was determined by Trypan blue 
exclusion.  PBMNC were cultured in triplicates (2x10
5/well) in round-bottomed 96 
well plates, in RPMI-1640, containing 10% human AB serum (Sigma, Cat N
o H-
4522), 1X  of  Penicillin-Streptomycin-Glutamine (100X) (Invitrogen, Cat N
o 10378-
016),  1mM Sodium Pyruvate (Invitrogen, Cat N
o 11360-039) hereafter referred to as 
complete medium (CM). PBMNC were cultured with either TT, PPD, C. alb, Ctrl1 or 
Ctrl2. PBMNC cultured without antigen were used as controls. At day 5, cells were 
pulsed with 1 µCi/well of [methyl-3H] thymidine (Amersham Biosciences, Cat N
o 
TRA120-1MCI) and proliferative activity was measured after 18h using a scintillation 
counter. The response is reported as stimulation index (SI), mean cpm of antigen-
stimulated cultures/ mean cpm of control. A SI of 3 or higher was taken as a positive 
response. Comparisons between post-vaccine and pre-vaccine antigen-specific 
responses were made from the fold increase (FI) in the SI (post-vaccine SI/pre-
vaccine SI) and SDs of the two compared triplicates. The symbol (-) indicates no 
response and was given when FI < 1; the symbol (=) indicates stable response and 
was given when FI=1 or FI is < one SD from 1; finally, the symbols (+), (++) and 
(+++) indicate different degrees of response and were given when 1 < FI < 2, 2 ≤ FI < 
4 and FI ≥ 4 respectively. 
 
1.3.4  Cytokine measurement by Enzyme-linked immunosorbent spot 
(ELISPOT) 
 
ELISPOT plates (MAIPS4510; Millipore) were pre-treated with 70% ethanol 
50µl/well for 2 minutes. They were than washed three times with sterile phosphate 
buffered saline (PBS) and coated overnight at 4°C with 10µg/ml of mAb against 
either human IFN-γ (1-D1K), IL-13 (IL-13-I) (both from Mabtech, Sweden, Cat N
o   48
3420-3-1000 and Cat N
o 3470-3-1000 respectively), or IL-2 (from IL-2 ELISPOT pair 
Cat N
o 551884, BD Biosciences). Antibodies were diluted in sterile PBS and 100µl 
were added per well. After washing and blocking for 1 hour with CM, 2x10
5 viable 
PBMNC were added in triplicate with either antigen or medium alone. After 40h, cells 
were discarded, wells were washed 6 times with PBS, and the following biotinylated 
mAbs were then added:  anti-human (α-h)-IFN-γ and α-h-IL-13 (both from Mabtech: 
Cat N
o 7-B6-1 and IL-13-II respectively); α-h-IL-2 (from IL-2 ELISPOT pair Cat N
o 
551884, BD Biosciences). Antibodies were diluted in PBS/1% Bovine Serum 
Albumin (BSA) and used at the manufacturer’s recommended concentrations.  Plates 
were placed at 37
oC and left for 1.5 hours. They were then washed again 6 times with 
PBS and 100µl of streptavidin-alkaline phosphatase (Mabtech, 40ng/well) diluted in 
PBS/1% BSA were added to each well. After one hour plates were washed with PBS 
(6 times) and a chromogenic substrate (BCIP/NBT substrate kit, Zymed Laboratories 
Inc.,USA) was added. Spot formation was inspected by eye and once spots developed 
the chromogenic reaction was blocked by washing the plates with distilled water. The 
number of spots was counted using a computer-assisted video image analyzer 
(Autoimmun Diagnostika GmbH, Germany). Antigen-specific responses are reported 
as the number of spots per 2x10
5 PBMNC in antigen-stimulated cultures minus the 
number of spots in the corresponding control. The average number of spots in 
triplicate control wells was always <5. Responses were considered positive if: (mean 
number of spots in triplicates of antigen-stimulated cultures) – (mean number of spots 
in the control) ≥ 10 per well, and >the mean number of spots in the control +2S.D. 
Comparisons between post-vaccine and pre-vaccine responses were done applying 
criteria used to evaluate proliferative responses (see above). 
 
1.3.5  Functionality of cryopreserved PBMNC after thawing 
 
Although viability of defrosted cells was always very good (around 90%), an 
important issue was to check whether the functionality of cells was affected either by 
the processes of freezing and thawing or by the duration of storage. To address these 
points, antigen-specific proliferative responses and IFN-γ production (by ELISPOT) 
were studied using PBMNC freshly isolated from a healthy donor and were compared 
to the responses from the same PBMNC which had been cryopreserved and were   49
defrosted one, two and twelve weeks later. To check for intra-assay variability, in 
each case two frozen vials were defrosted and used in parallel in the assays. The 
results of these experiments are illustrated in Figure 1.5. It is clear that the process of 
freezing and thawing did not affect PBMNC in their potential to proliferate or to exert 
effector functions (IFN-γ production) in response to the recall antigens TT and PPD or 
to a mitogenic stimulus (phytohaemagglutinin, PHA). In fact the levels of 
proliferative activity and cytokine production of crypreserved PBMNC were 
comparable to those of fresh PBMNC.  More importantly, they did not decrease over 
time in cells kept in liquid N2 Figure 1.5.A. At each time point proliferative responses 
and IFN-γ production were comparable between the two samples assayed in parallel 
(Vial 1 versus Vial 2). The only exception was found at week 2, when proliferative 
activity was expressed as stimulation index (Figure 1.5.A). In this case a lower degree 
of background proliferation of the un-stimulated control resulted in a significantly 
higher S.I. for PBMNC from Vial 2, although the absolute CPMs were comparable. 
Cytokine production by fresh and cryopreserved PBMNC was studied further in two 
additional independent experiments (Figure 1.5.C). PBMNC isolated from two 
healthy volunteers (subject 2 and 3) were used to assess responses to TT by IFN-γ 
ELISPOT. Fresh PBMNC were compared to PBMNC cryopreserved for 1 week 
(subject 2) or for five weeks (subject 3). Confirming what was found in the previous 
experiment, no significant differences were found between fresh and cryopreserved 
PBMNC. Overall these results validate the use of cryopreserved PBMNC for the 
purposes of our study.   50
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Figure 1.5. Functional comparisons between fresh and cryopreserved PBMNC. 
Proliferation and IFN-γ ELISPOT assays (see above for details of the protocols) were used to compare 
functional behaviour of fresh and cryopreserved PBMNC isolated from healthy donors. Proliferative 
responses (A) and IFN-γ production (B) upon in vitro culture with medium only (control), with a 
mitogen (PHA) or with recall antigens TT and PPD were compared between PBMNC freshly isolated 
from one volunteer and the same PBMNC cryopreserved and defrosted one, two and twelve weeks 
later. To check for intra-assay variability, in each case two frozen vials were defrosted and used in 
parallel in the assays. (C) In vitro IFN-γ production in response to TT (10µg/ml) was compared 
between fresh PBMNC and PBMNC cryopreserved for 1 week (subject 2) or for five weeks (subject 3). 
Proliferative activity was measured by 
3H-thymidine incorporation after 6 days of in vitro culture and 
reported for each time point as the mean value of counts per minute (CPM) or as stimulation index (SI) 
in triplicate cultures ± SD. For IFN-γ ELISPOT data for each time point represent the mean number of 
spots ± SD of triplicate wells of antigen-stimulated cultures after subtracting the mean number of spots 
in the corresponding un-stimulated negative control. The mean number of spots in the controls was 
always <5 spots per 2 x 10
5 PBMNC. N.D. Not done   51
1.3.6  Generation of antigen-specific T cell lines 
 
PBMNC were isolated from two healthy donors (D1 and D2) who, in a preliminary 
screening, showed strong proliferative responses against TT and PPD respectively 
(see Table 1.2 below).  
 
 
Table 1.2. Pre-screening of proliferative responses to TT and PPD in two immune healthy 
subjects. Proliferative activity of PBMNC isolated from two healthy volunteers (D-1 and D-2 in 
response to TT or PPD stimulation, was measured by 
3H-thymidine incorporation after 6 days of in 
vitro culture and reported for each time point as the mean value of counts per minute (CPM) or as 
stimulation index (SI) in triplicate cultures ± SD.   
 
To generate antigen-specific cell lines, PBMNC from D1 and D2 were cultured in CM 
in the presence of TT and PPD respectively (10µg/ml) at 2x10
5/well in round-
bottomed 96 well plates. Human recombinant IL-2 (20 U/ml) (R&D Systems, Cat N
o 
202-IL-050) was added at day 7 and 9 and medium replaced if necessary. At day 14 
cells were harvested, pooled and counted. Viable cells were then re-stimulated with 
antigen plus irradiated (40 Gy) autologous PBMNC as antigen presenting cells 
(APCs) at 1 to 3 ratio in 12 or 24 well plates. IL-2 was added at day 5. Lines were 
maintained by repeating this 14-day cycle of re-stimulation with antigen followed by 
culture in IL-2. 
 
 
1.3.7  Antigen specificity of T cell lines and identification of restricting HLA 
molecules 
 
The antigen specificity of the T cell lines was checked by a 3-day proliferative assay, 
performed as described above, using 2.5 x 10
4 T cells plus irradiated (40 Gy) 
  D-1 D-2 
  CPM   S.I.  CPM  S.I. 
  MEAN STDEV MEAN STDEV MEAN STDEV MEAN STDEV 
Unstimulated  647 239      863  44     
TT 1µg/ml  60161  3316  93.0  5.1 121797  22622 141  26.2 
PPD 10µg/ml  30189 13083  46.7  20.2 106310  7219  123.2  8.4   52
autologous PBMNC as APCs at 1 to 3 ratio in round-bottomed 96 well plates. 
10µg/ml of antigen was added in each well. PHA (10µg/ml) was used as positive 
control.  To identify the restricting HLA isotype of the T cell lines, 10µg/ml of mAb 
directed against HLA-DR (L243), HLA- DP (B7/21.2) or HLA class I (W6/32) (all 
from Cancer Research UK) were added to the cell suspension one hour prior to 
addition of the antigen and kept in the medium for the duration of the proliferative 
assay. 
 
 
1.3.8  Flow cytometry analysis 
 
1.3.8.1  CFSE labeling and cell division analysis.  
 
Cryopreserved PBMNC were thawed and counted as described above (see 
Proliferative responses). Then they were labeled in vitro with CFSE (Cell Trace, 
Molecular Probes, Ivitrogen, Cat N
oC34554) a modified protocol adapted from Lyons 
AB & Parish CR  
96. Briefly, cells were resuspended in RPMI 1640 at 10 x 10
6 
cells/ml. CFSE was added to cell suspensions at a final concentration of 5µM, and  
tubes were transferred into a water bath at 37 
oC. They were mixed occasionally and 
after 10 minutes ice cold FCS was added (1/2 of the initial volume) and tubes were 
left on ice for 5 minutes to quench the reaction. Two washes followed, one with RPMI 
and the second with PBS. Cells were finally resuspended in CM and cultured in six 
replicates (2x10
5/well) with CM alone or with antigen.  At indicated times, cells from 
replicate wells were pooled, washed and stained with the following antibodies: anti-
human CD3-PerCP (clone SK7), CD4-APC (clone RPA-T4) and CD25 PE (clone M-
A251) (all BD Biosciences) or with their respective mouse immunoglobulin isotype 
controls. Samples were analyzed on a FACSCalibur flow cytometry using 
CELLQUEST software (both from BD Biosciences). An initial gating based on 
forward and side scatter characteristics included both resting lymphocytes and blasts. 
A minimum of 10,000 CD3-positive and CD4 positive gated events were acquired and 
analyzed for CFSE contents and CD25 surface expression. 
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1.3.8.2  Phenotypic analysis 
 
 
White blood cell counts were done using an automated cell counter and analyzer at 
the Southampton General Hospital. For phenotype analysis, cryopreserved PBMNC 
were thawed, washed with PBS (5 minutes at 1600 RPM), resuspended in 50-100µl 
PBS and stained for 20 minutes on ice using the manufacturer’s recommended 
concentrations of the following antibodies: anti-human CD3-PerCP (SK7), CD4-APC 
(RPA-T4), CD8-APC (RPA-T8), CD14-APC (M5E2), CD19-APC (HIB19), CD25 
PE (M-A251), CD45RA (HI 100), CD45RO (UCHL1), CD56-APC (B159), CD80-
FITC (L307.4), CD86-PE (2331, FUN-1) and HLA-DR-PE (G46-6, L243)  (all BD 
Biosciences) or with their respective mouse immunoglobulin isotype controls. Cells 
were then washed once with PBS (5 minutes at 1600 RPM), fixed with PBS/1% 
formaldehyde and analyzed on a FACSCalibur flow cytometer using CELLQUEST 
software (both from BD Biosciences). Based on forward and side scatter 
characteristics, an initial gating was used to exclude dead cells and debris. A 
minimum of 20,000 viable cells was acquired.  
 
 
1.3.9  Antibody measurement by Enzyme-linked immunosorbent assay (ELISA) 
 
Ninety-six well flat-bottomed plates (ImmunoSorp plates, Nunc, Denmark.Distributed 
by Invitrogen) were coated overnight at 4°C with either 2.5 µg/ml of TT, 10µg/ml of 
PPD or 10µg/ml of C. alb. Antigens were diluted in ELISA coating buffer (Na2CO3 
(anhydrous) 1.58g, NaHCO3 2.92g, dH2O 1litre. pH 9.5) and 100µl were distributed 
into each well. Plates were then washed once with 200ml/well PBS-tween (0.01%) 
and blocked for 90’ at 37
oC with 200ml/well PBS/1% BSA. After washing once with 
PBS-tween (0.01%), serial dilutions of serum samples (100µl/well) or appropriate 
standards in at least four replicate wells were added.  Antibody standards were: TT, 
tetanus antitoxin human immunoglobulin (Tetanus Antitoxin Human Serum NIBSC 
code: 76/589, NIBSC); PPD, serum from a healthy individual showing relatively high 
anti-PPD antibody titers; C. alb, serum from a known antibody-positive subject 
(kindly provided by Dr R.Hobson, Mycology Reference Centre, University of Leeds, 
UK). Plates were kept 90 minutes at 37
oC and then washed 4 times with PBS-tween   54
(0.01%) prior to adding a 1/2000 dilution (100µl/well) of a horse-radish peroxidase 
(HRP)-conjugated monoclonal anti-human IgG (Fc) (The Binding Site, Birmingham, 
UK) which was used for detection. Following 1h incubation at 37
oC, plates were 
washed 4 times and incubated with 100µl/well substrate (citric acid (anhydrous) 
4.68g, Na2HPO4 7.30g, dH2O 1litre. pH 5.5) until a colour change was detected. The 
reaction was then stopped by adding 80µl/well 2.5M H2SO4. Plates were read using a 
Dynex MRX Platereader (Dynatech Instruments Inc., Santa Monica, USA) set at 
490nm wavelength. For TT, results are expressed in I.U./ml. For PPD and C. alb, 
results are expressed in arbitrary units (A.U.)/ml. Comparisons between post-vaccine 
and pre-vaccine antigen-specific responses were done using fold increase in titers 
(post-vaccine response/pre-vaccine response) and SDs of the two compared replicates. 
Symbols indicating no response (-), stable (=) or different degrees (+ to +++) of 
positive response, were assigned using the same criteria as for the cellular responses.   55
1.4  Results 
  
1.4.1  Vaccine-specific and bystander proliferative responses of Tmem cells 
following booster vaccination with TT 
 
The kinetics of the TT-specific proliferative responses over 16 weeks following 
booster vaccination with TT are shown for six representative cases (Figure 1.6.A).  
Importantly, results were reproducible using samples thawed from stocks on two 
different occasions, as shown for a representative case in Figure 1.6.B.  
Pre-existing immunity, as indicated by a positive response at week 0, was evident in 
all, but at different levels (Figure 1.6.A).  Increased responses were detected after 
vaccination but the time to peak responses varied from 2-12 weeks and the dynamic 
complexity of the responses was striking. Surprisingly, parallel kinetics were 
observed for proliferative responses against two unrelated antigens for which pre-
existing immunity was also evident, PPD and C. alb (Figure 1.6.A).  Parallel kinetics 
were seen in individuals with early (cases 5, 3,10) or late (cases 6, 8, 9) responses to 
TT. In patient 8 who lacked pre-existing immunity against C. alb, bystander 
proliferative responses did not develop arguing that Tmem cells are required. In support 
of that, no responses against control antigens (Ctrl 1 and Ctrl 2) without pre-existing 
immunity were detected. It appears therefore that vaccination expands both specific 
and non-specific Tmem coordinately, and that contractions also occur in parallel.  These 
contractions were observed in various individuals (e.g. case 5 at wk 4, case 3 at wk 8, 
case 10 at wk 8 etc.) (Figure 1.6.A) and were not due to low viability of thawed cells, 
which was always ~ 90%.  They were observed also when the assay was done using 
fresh PBMNC (Figure 1.6.C), for which viability exceeded 95%, excluding any other 
differential loss of functionality during cryopreservation. Finally they were still 
observed when higher (super-optimal) doses of antigen were used (Figure 1.6.C, time 
point wk 4), arguing against a drop in assay sensitivity at those particular time points. 
Overall these contractions seem to represent a genuine phenomenon, which at least in 
some individuals can been seen as the natural decline of the immune response 
following the peak.  
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Figure 1.6 Kinetics of vaccine-specific and bystander proliferative responses of Tmem cells 
following booster vaccination with TT.  
(A) From 
5 . Six representative examples are shown. Vaccination (week 0) induces early (subjects 5, 3 
and 10) and late (subjects 6, 8, and 9) TT-specific responses. Parallel kinetics were observed in the 
responses against two unrelated antigens (PPD and C. alb) for which pre-existing immunity was 
evident, but no responses were detected against control antigens (Ctrl 1 and Ctrl 2) with no evident pre-
existing immunity.  
(B) Proliferative response to TT in individual 3, measured in two different occasions. 
(C) Proliferative responses of freshly isolated PBMNC to super-optimal (10µg/ml) and sub-optimal 
(0.1µg/ml) concentrations of TT in individual 13. 
Proliferative activity was measured by 
3H-thymidine incorporation after 6 days of in vitro culture and 
reported for each time point as the mean value of stimulation index (SI) in triplicate cultures ± SD.   57
Proliferative responses of the 12 subjects to the 3 antigens TT, PPD and C.alb are 
shown in Figure 1.7.A and 1.7.B. Due to the variable kinetics, the time of maximum 
response against TT varied from 1-12 weeks, and, in order to condense the data, 
responses against the other antigens are shown at this time. Responses have been 
summarized and graded (+ to +++) in terms of fold increases over pre-existing levels, 
as defined in Section 1.3.3 of Methods (Figure 1.7.B). Although this grading 
documents the significant changes occurring, it minimizes the apparent responses of 
subjects, such as case 10, with a high initial level (SI ± SD = 57.9 ± 4 ) which clearly 
increased to an SI = 92.2 ± 1.8 (Figure 1.7.A). In contrast, it maximizes the apparent 
responses of subjects, such as case 4, with a very low pre-existing response (SI = 2.2 
± 0.3) but with a clear increase (SI = 9.9 ± 1.0). Overall, 12/12 subjects showed 
significantly increased responses to the TT vaccine, and the majority (11/12) had 
increased responses to at least one of the other non-vaccine antigens. For example, 
cases 2, 5 and 11, with strong responses to TT and pre-existing immunity to PPD and 
C. alb, showed high bystander effects. The single subject (case 1) who failed to 
expand the pre-existing response to PPD or C. alb had responded relatively weakly to 
the TT vaccine (Figure 1.7.A and B). 7/12 subjects responded to all 3 antigens.  
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Figure 1.7. From 
5 .Vaccine-specific and bystander proliferative responses of Tmem cells in twelve 
individuals following booster vaccination with TT. 
(A)  Responses are shown at the week of maximal TT response, and are compared to the pre-vaccine 
(Wk 0) response.  Proliferative activity was measured by 
3H-thymidine incorporation after 6 days of in 
vitro culture and is reported as the mean value of stimulation index (SI) in triplicate cultures ± SD.  
(B)  Summary of proliferative responses against PPD and C. alb at the week of maximal TT response.  
The week of maximal TT response is reported for each individual. Symbols indicating no response (-), 
stable (=) or different degrees (+ to +++) of a positive response, were given according to the criteria 
stated in Materials and methods.   59
1.4.2  Lack of cross-reactivity among the antigens  
 
To exclude the possibility that the observed proliferative responses against the 
unrelated antigens PPD and C. alb were due simply to cross-reactivity, two antigen-
specific T cell lines, D1-TT and D2-PPD, were generated by repeated stimulation in 
vitro of PBMNC with TT and PPD respectively.  Antigen specificity was then tested 
in a short term proliferative assay. As shown in Figure 1.8.A, the D1-TT cell line 
specifically responded only to TT but not to PPD or C. alb while the D2-PPD cell line 
specifically responded to PPD but not to TT or C. alb. Both T cell lines strongly 
proliferated in the presence of PHA, used as positive control. Taken together these 
data indicate lack of cross reactivity among the antigens used in the present study.  
 
1.4.3  Nature of the responding T cells  
 
To identify the restricting HLA element and the phenotype of the responding cells, the 
proliferation assay was repeated for D1-TT in the presence of monoclonal antibodies 
(mAbs) directed against human MHC antigens (Figure 1.8.B). L243 and B7/21.2 
recognize two class II molecules, HLA-DR and HLA- DP respectively. W6/32 
recognizes HLA class I molecules. The proliferative response to TT was strongly 
inhibited (>95%) only in the presence of L243. This identifies HLA-DR as the 
restricting class II element involved in the presentation of antigen and CD4
+ helper T 
cells as the population of lymphocytes responding in vitro to TT.   60
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Figure 1.8 From 
5. 
(A). Lack of cross-reactivity among TT, PPD and C. alb antigens. To exclude cross-reactivity 
among the antigens used, two different T cell lines D1-TT and D2-PPD were generated from PBMNCs 
of two healthy donors, by repeated cycles of in vitro stimulation with TT and PPD respectively, as 
described in Materials and methods. Their antigen specificity was then tested in a three-day in vitro 
proliferative assay. Proliferative activity was measured by 
3H-thymidine incorporation and is reported 
as counts per minute (cpm) in triplicate cultures ± SD.  
(B). Identification of HLA-DR as the restricting MHC molecule of the T cell lines.  To identify the 
restricting HLA isotype of the T cell lines, antigen presentation by autologous APCs was assayed by 
repeating the proliferative assay after addition of mAbs against HLA-DR (L243), -DP (B7/21.2) or 
HLA class I (W6/32) at the beginning of the culture time. The proliferative response of the D1-TT to 
TT was strongly inhibited only when the HLA-DR-specific mAb L243 was added to the culture.  
 
 
 
1.4.4  Vaccine-specific and bystander cytokine production by Thmem cells 
following booster vaccination with TT 
 
IFNγ, IL-2, IL-5 and IL-13 ELISPOTs were used to study the effect of vaccination 
with TT on the ability of the T-cell population to produce cytokines in response to 
antigen in vitro. IFNγ and IL-2 are generally considered to indicate Th1 responses, 
while IL-13 mainly reflects Th2 activation 
97. In initial experiments, we used both IL-  61
5 and IL-13 ELISPOT assays to analyse responses to vaccination in healthy 
volunteers boosted with TT. In four subjects, we confirmed that production of IL-13 
correlated closely with that of IL-5, a classical Th2-associated cytokine (Figure 1.9).  
However, while in one subject (subject 2) IL-5 and IL-13 responses were comparable, 
in all three remaining subjects (4, 7 and 9) IL-13 ELISPOT showed higher sensitivity, 
especially when low levels of cytokine production were detected (subject 4). For this 
reason, and also to reduce the number of cells required to set up these assays, IL-13 
ELISPOT only, was thereafter used. 
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Figure 1.9. Kinetics of TT-specific IL-5 and IL-13 production by Thmem cells following booster 
vaccination (week 0) with TT.  
Both IL-5 and IL-13 are produced and detected by ELISPOT assay following in vitro re-stimulation 
with TT of PBMNC taken from four healthy individuals boosted with TT. These responses show 
parallel kinetics which reflect a Th2 component in the vaccine-specific immune response. However IL-
13 ELISPOT appears to offer higher sensitivity especially when low responses to the vaccine are 
detected (see subject 4). To simplify the graphs, responses to protein Ctrl1 or Ctrl2 are not shown, but 
they were always below 5 spots / 2 x 10
5 PBMNC. Data for each time point represent the mean number 
of spots ± SD of triplicate wells of antigen-stimulated cultures after subtracting the mean number of 
spots in the corresponding negative control. The mean number of spots in the controls was always < 5 
spots per 2 x 10
5 PBMNC. 
 
 
The effect of vaccination with TT on the ability of the T-cell population to produce 
cytokines in response to TT and to unrelated antigens in vitro, also revealed complex 
dynamics.   Kinetic data from 2 representative subjects (cases 3 and 9) showed   62
parallel induction of IFNγ, IL-2 and IL-13 (Figure 1.10) in response to TT. Production 
of all three cytokines is consistent with a mixed Th1 and Th2 response (Figure 1.10).  
Cytokine production generally mirrored proliferative responses (Figure 1.6), with 
early and late peaks. However, in case 9, there was more evidence of cytokine-
producing T cells at week 2, without a significantly increased proliferative response 
above the relatively high pre-existing levels.   
For both cases, bystander cytokine production against PPD was also observed, with a 
similar pattern to the proliferative responses (Figures 1.6, 1.7 and 1.10).  PPD induced 
high IFNγ levels, as reported previously 
98, but also IL-13, indicating a mixed 
Th1/Th2 response. Cytokine production against C.alb in these subjects showed less 
consistent changes, reflecting the more modest proliferative responses (Figure 1.6).  
However, a significantly increased IL-2 response was detected in case 3, at 2 weeks 
post vaccination, the time of maximum response to TT (Figures 1.6, 1.7 and 1.10). In 
case 9, a significant IFNγ response was observed against C. alb at week 12, again in 
parallel with the high responses against TT and PPD (Figure 1.10).  
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Figure 1.10. From 
5. Kinetics of vaccine-specific and bystander cytokine production by Thmem 
cells following booster vaccination (week 0) with TT.  
Two representative examples are shown. Characteristic Th1 (IFN-γ and IL-2) and Th2 (IL-13) 
cytokines are produced following in vitro re-stimulation with TT and detected by ELISPOT assay. 
Parallel changes in the number of cytokine-producing cells are seen against PPD and (to a lesser extent) 
against C. alb, but not against Ctrl1 or Ctrl2. Data for each time point represent the mean number of 
spots ± SD of triplicate wells of antigen-stimulated cultures after subtracting the mean number of spots 
in the corresponding negative control. The mean number of spots in the controls was always <5 spots 
per 2 x 10
5 PBMNC. 
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Cytokine profiles against PPD and C. alb, for all subjects showing a response to TT, 
were measured at the point of maximum response to TT, which generally matched 
that of the proliferative response.  Data are shown in Figure 1.11.A as the number of 
spots/ 2 x 10
5 cells.  In Figure 1.11.B responses have been summarized and graded (+ 
to +++) in terms of fold increases over pre-vaccine levels, following the same criteria 
applied for the evaluation of proliferative responses, and the week of maximum 
response to TT is reported for each cytokine.  The pattern of cytokine production 
against PPD tended to mirror that against TT, with production of IFNγ, IL-2 and IL-
13 (Figure 1.11.A and B). Cytokine responses against C. alb were less common, 
probably due to a lower degree of pre-existing immunity. For example, subject 8 with 
no apparent pre-existing or post-TT vaccination proliferative response to C. alb 
(Figure 1.6), failed to produce IL-2, while this was readily produced in response to TT 
and PPD (Figure 1.11.A and B). The largest increase in the IFNγ response against C. 
alb was in subject 9 at week 12 (see above), which paralleled responses to TT and 
PPD. However, in contrast to TT and PPD, there was no detectable increase in IL-2 
and IL-13-producing T cells against C. alb at this time point (Figure 1.11.A and B).    64
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Figure 1.11. From 
5. Vaccine-specific and bystander cytokine production in twelve individuals 
following booster vaccination with TT.  
(A) Responses are shown at the week of maximal TT response and are compared to the pre-vaccine 
(Wk 0) response. Cytokine responses were measured by ELISPOT assay after 40h of in vitro culture 
and are reported as the mean number of spots ± SD of triplicate wells of antigen-stimulated cultures 
after subtracting the corresponding negative control. The mean numbers of spots in the controls were 
always <5 spots per 2 x 10
5 PBMNC. (B) Summary of cytokine responses against PPD and C alb at the 
week of maximal TT response. The week of maximal TT response is reported for each individual and 
for each cytokine. Symbols indicating no response (-), stable (=) or different degrees (+ to +++) of a 
positive response, were given according to the criteria stated in Materials and methods. 
ND, not done. 
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1.4.5  The increased numbers of vaccine-specific and bystander memory T cells 
detectable by ELISPOT after TT-vaccination, seem to reflect an in vivo 
expansion 
 
One question is whether the increased number of cytokine-producing cells observed in 
post-vaccine samples after 40h incubation in vitro with PPD or C. alb was by T cells 
expanded in vivo. An alternative explanation might be that Thmem cells against 
bystander antigens might not have divided in vivo, but could have been rendered more 
sensitive to specific antigenic proliferative signals in vitro.  To investigate this, we 
used CFSE labeling 
96 to track cell division occurring in vitro in CD3
+CD4
+ T cells 
from the blood of case 3, at Day 0 and 2 weeks post TT injection (the time of 
maximum response against TT, see Figures 1.6 and 1.10). We found that cell division 
did not occur during incubation with antigen for 40h in vitro, up to the point where 
cytokine production was measured (Figure 1.12), although cells could be all activated 
(CD25
+) and induced to divide if stimulated with PHA. The number of cytokine-
producing cells, as measured by ELISPOT, therefore reflects cells already existing in 
vivo. Booster vaccination has apparently increased functional antigen-specific and 
bystander Tmem cells in vivo, able to respond in vitro to TT or to PPD/C. alb 
respectively by proliferation and cytokine production.  
   66
 
Figure 1.12 CFSE-based cell division analysis.  
PBMNC from subject 3 pre-vaccination (Wk 0) and after a TT boost at the peak TT-specific 
proliferative and cytokine responses (Wk 2) (see Fig 1.6 and Fig 1.10), were labeled with CFSE and 
stimulated in vitro with either TT, PPD or C. alb. After 40h, cells were harvested and surface-stained 
for CD3, CD4 and CD25. All dot plots are gated on CD3
+CD4
+ cells in the lymphocytes and blasts 
region. Cells are analyzed for CFSE content and CD25 expression and % of positive cells are indicated. 
No indication of cell division is evident at 40h in either Wk 0 or Wk 2 antigen-stimulated cultures. 
 
 
1.4.6  Stable immunophenotypic profile of blood cells during the antigen-
specific responses to vaccination with TT 
 
To investigate any relationship between the observed kinetic pattern in the antigen-
specific responses and possible changes in the number and/or phenotype of 
immunologically relevant cell subsets in the peripheral blood, a detailed phenotypic 
analysis was carried out at each time point in one individual (case 12) and analyzed in 
parallel with IFN-γ, IL-2 and IL-13 antigen-specific responses. Results are shown 
(Figure 1.13) up to wk 4 (the remaining time points are not shown for clarity). While 
a clear expansion in the number of TT-specific and bystander Tmem cells measured by 
ELISPOT is visible at week 1, followed by a down-regulation to pre-vaccine levels at 
week 2 (Figure 1.13.A), a parallel remarkable stability was found in the number and 
phenotype of all the analyzed cell subsets (Figure 1.13.B). In fact, no significant 
changes were found in the number of total white cells, or in the number of 
lymphocytes and monocytes in the blood (Figure 1.13.B). No significant changes 
were found in the percentages of CD3
+CD4
+ T lymphocytes, known to be the major 
population of cells responding in vitro to TT and PPD
21,22 and in the proportion of   67
CD14
+ monocytes which constitute together with CD19
+ B cells the major 
populations of antigen presenting cells within the PBMNC.  
Expression of the activation marker CD25 within the total PBMNC and within the 
CD3
+ lymphocyte population was checked and found to be unchanged (Figure 
1.13.B). The level of MHC and co-stimulatory molecules was also measured and no 
change in the total percentages of cells expressing HLA-DR or the co-stimulatory 
molecule CD86 was detected (Figure 1.13.B). Finally, no significant changes were 
found in the percentages of T regulatory cells defined here as CD3
+, CD4
+, CD25
High, 
CD45R0
High (Figure 1.13B). 
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Figure 1.13. From 
5. Immunophenotypic profile of blood cells during the antigen-specific 
responses to vaccination with TT in subject 12. 
(A) Kinetics of IFN-γ, IL-2 and IL-13 antigen-specific responses against TT, PPD and C. alb in subject 
12 vaccinated with TT as measured by ELISPOT. Data for each time point (0, 1, 2 and 4 weeks) 
represent the mean number of spots ± SD of triplicate wells of antigen-stimulated cultures after 
subtracting the mean number of spots in the corresponding negative control. The mean numbers of 
spots in the controls were always lower then 5 spots per 2 x 10
5 PBMNC. 
(B) Blood counts and phenotype of immunologically relevant cell subsets at the corresponding time 
points.  
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This analysis points to no gross changes in relative proportions, composition or 
activation status of cell populations during vaccination.  An analysis of phenotypic 
changes in activation markers within selected populations of CD4
+ memory T cells or 
subtypes of TCM, TEM cells using multi-color flow cytometry might be more revealing 
and is now planned on a new cohort of vaccines. 
 
1.4.7  Antibody responses 
 
Measurement of the antibody responses against TT showed the expected boost after 
vaccination, with a maximum at or near week 2 (Figure 1.14). Levels were variable 
but all subjects showed a significant increase to a plateau followed by a very slow 
decline over 20 weeks (Figure 1.14), confirming other studies 
88,95. The most dramatic 
change was observed in two individuals (7 and 11) showing pre-vaccination TT-
specific antibody titers below the level of 0.1 I.U. /ml, known to be required for full 
protection (fold increase at wk 2 = 162 and 135, respectively). Interestingly, the same 
individuals had shown the strongest IL-13 responses in the ELISPOT assay (see 
Figure 1.11). In contrast to TT, there was no significant change in antibody levels 
against PPD or C. alb which remained remarkably stable. These findings indicate a 
dependence of antibody formation by B cells on specific antigen, and argue for 
restriction of a functional bystander effect to T cells.   70
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Figure 1.14. From 
5. Kinetics of antigen-specific antibody responses as measured by ELISA in 
twelve individuals following booster vaccination (week 0) with TT.  
A boost in the levels of TT-specific serum IgG was evident in all the vaccinated subjects, with a 
maximum at the indicated week, but no significant changes were detected in either PPD- or C.alb-
specific antibody responses. Data for each time point represents the mean value of at least four replicate 
wells. SD bars are not shown for clarity.  Symbols (+ to +++) indicate different degrees of positive 
responses analyzed at the week of maximal TT response (indicated), as compared to the pre-vaccine 
(week 0) response, and were given according to the criteria stated in Materials and methods.   71
 
1.5  Discussion 
 
The control of memory T cells has obvious implications for natural and vaccine-
induced immunity. The mechanisms of induction and, above all, of maintenance of T 
cell memory, although widely investigated, remain unclear. Whether or not antigen is 
required for the maintenance of memory T cells is still debated, although in mice 
long-term persistence of CD4
+ and CD8
+ memory T cells can occur in antigen-free 
MHC class II-, and class I-deficient mice, respectively 
68,69. In humans, vaccinia-
specific humoral and cellular responses can be detected for decades after smallpox 
vaccination in the absence of re-exposure to the virus 
65-67, supporting the idea that 
antigen-independent mechanisms may contribute to the maintenance of 
immunological memory.  
 
To study antigen-independent activation of memory T cells in vivo in human subjects, 
we have assessed the impact of TT boost vaccination on the kinetics of populations of 
memory T cells specific for TT, and also on the kinetics of memory T cells specific 
for two common un-related recall antigens, PPD and C.alb. We have focused our 
analysis on Thmem cells which are known to be the population responding to TT and to 
PPD in vitro 
99,100. Our data support the view that human Thmem cells are susceptible 
in vivo to stimulation from surrounding Thmem cells which are responding to specific 
antigen. This bystander response has parallel kinetics to the specific response, and is 
likely to be mediated by cytokines. In this respect the immune system uses Thmem cells 
to add an innate “infectious” element to the specific response. Although there is a 
tempting parallel with infectious tolerance 
101, this cannot be simply drawn. Infectious 
tolerance has been studied mainly at the point of priming and appears to require 
presentation of both specific and bystander antigens by the same DC 
102. For Thmem 
stimulation, the bystander antigens apparently need not be present. A hypothetical 
model describing the bystander activation of Thmem cells is depicted in Figure 1.15. 
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Figure 1.15. Bystander activation/proliferation of CD4
+ memory T cells: a hypothetical model 
(see text for a description) 
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In vitro proliferative responses against TT and PPD were detected at various degrees 
in all subjects prior to vaccination with TT, indicating pre-existing immunity probably 
generated by the prophylactic TT- and BCG-vaccinations that all the individuals had 
received. Pre-existing immunity against C. alb would depend on natural exposure, and 
initial proliferative responses were more heterogeneous (Figure 1.7).  
 
In terms of immune protection, the ability of the wider bystander population to secrete 
pro-inflammatory cytokines at the site of infection would enhance the effectiveness of 
the specific response. Clearly it is now necessary to dissect the CM and EM 
components of these Thmem populations in human subjects (see Section 1.6.1).  
 
With regard to the maintenance of Thmem cells, a speculative hypothesis could be that 
periodic bystander expansions of Thmem cells ultimately contribute to their long-term 
persistence. This point would be probably difficult to address in humans, and in this 
case a well defined mouse model could provide more definitive answers (see Chapter 
2). 
The ability of human CD4
+ Tmem cells to respond directly to cytokines has been 
suspected for some time from in vitro data 
75. However, the focus in mouse models 
has been mainly on CD8
+ Tmem cells. The latter are clearly susceptible to cytokine 
stimulation, with the main mediators being IL-15 and IL-7 
34,103. In fact, “bystander” 
activation of human CD8
+ T cells has been suggested in a recent study of responses to 
two different latent herpes viruses where contemporaneous co-fluctuations of virus-
specific CD8
+ T cells were observed without perturbation of the total number or 
phenotype of CD3
+ T cells 
104. This stability in the CD3
+ T-cell population seen 
during spontaneous activation of immunity against latent herpes viruses was also 
evident in our study of the effects of vaccination (Figure 1.13).    
 
In contrast to CD8
+ T cells, it has been proposed that CD4
+  Tmem do not need 
cytokine signals for survival or expansion 
105.  However, CD4
+ Tmem cells do express 
IL-7 receptors, and it has been reported that they are regulated by signaling via IL-7, 
with an overlapping influence of TCR signals 
106. Dependence on IL-7 for generation 
and survival of transgenic CD4
+ Tmem cells has also been observed 
107, with evidence 
for involvement in the transition from effector to memory T cells 
108.   
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A close parallel to our observations in human subjects was described recently in a 
mouse model where infection with Leishmania donovani led to expansion of 
adoptively transferred transgenic OVA-specific memory CD4
+ T cells 
109.  In this 
case, OVA antigen was required, possibly to maintain the transferred cells, whereas in 
our case it is unlikely, but not impossible, that PPD or C alb antigens or cross-reactive 
antigens persist in vivo. While definitive data on generation and survival of Tmem cells 
can be obtained from transgenic and knock out mice, it is difficult to mimic the 
situation in human subjects who have a normal Tmem repertoire under continuous 
exposure to environmental antigens. Perhaps in this case, data gleaned from human 
subjects, although more difficult to manipulate, can be illuminating.  
 
Our data on the behavior of human Thmem tie together several previous observations 
on T-cell responses following vaccination with TT 
110, including the fact that transient 
expansion of TT-specific T cells occurred during a flu-like illness 
99.   It presents a 
problem for evaluation of specific memory responses to vaccines, since cells could be 
expanding simply as bystanders.   It will be necessary next to determine if there are 
phenotypic or functional features which distinguish the T cell population responding 
to specific antigen from the bystander population, by analyzing  isolated 
subpopulations.   One particular question will be the balance between TEM and TCM in 
the two responses. 
  
While the bystander Thmem can secrete cytokines, and could potentially influence B 
cells, no increase in bystander antibody was evident (Figure 1.14). This would appear 
to argue against the proposal, again derived from subjects vaccinated with TT, that 
antigen-independent serological memory can be maintained by bystander activation of 
memory B cells 
95.  Our data are more consistent with a study on the effects of a 
booster injection of diphtheria vaccine on diphtheria- and tetanus toxoid-specific B 
cell responses, which showed a rise in the antibody response only against the 
immunizing antigen
111. However, it remains possible that activation of B cells is 
occurring, which could contribute to survival, but that no significant antibody results. 
Our data indicate that B cells are dependent on engagement of antigen by the B-cell 
receptor before they can receive the help apparently on offer from stimulated Thmem. 
Without this control, the antibody response would perhaps be too easily induced, with 
possible autoimmune consequences.  75
 
1.6  Future studies in humans 
 
1.6.1  Further phenotypic and functional characterization of vaccine-specific 
and vaccine-stimulated bystander CD4
+ memory T cells in human healthy 
volunteers following booster vaccination with tetanus toxoid 
 
Our observation that CD4
+ memory T cells are susceptible to bystander activation 
during a recall immune response raises a crucial question about the nature of these 
cells and the role that they might play in vivo. Of particular interest are stage of 
differentiation, functionality and potential life-span of vaccine-stimulated bystander 
CD4
+ memory T cells as opposed to vaccine-specific CD4
+ memory T cells.  
 
As discussed in the Introduction (see Sections 1.1.6, 1.1.7, 1.1.8) expression or lack of 
expression of a number of surface markers has been used to phenotypically define 
distinct populations of CD4
+ and CD8
+ T cells at different stages of differentiation 
112. 
Markers can also delineate distinct functional subtypes of memory T cells, such as 
TCM and TEM.  For CD4
+ T cells, functionality is generally assessed by the ability to 
proliferate and/or to produce various cytokines. A correlation has been shown 
between proliferation capacity and pattern of cytokine secretion, such as IL-2 
secretion.  In viral infections, an emerging concept is that T cells able to 
simultaneously produce more that one cytokine (multifunctional or polyfunctional) 
can play a major role in vaccine-induced immune protection. This has been 
demonstrated for CD8
+ T cells in a study of vaccinia virus immunization against 
smallpox 
113, and for CD4
+ T cells in a mouse model of Leishmania major infection 
114. There is also considerable interest in defining the contribution of TCM and TEM to 
vaccine-induced long term immune protection.  
 
To gather information about the potential life span of antigen-specific T cells, two 
markers are often considered: the subunit α of the interleukin 7 receptor (IL-7Rα) and 
the anti-apoptotic molecule Bcl-2. Expression of IL-7Rα identifies cells able to 
respond to IL-7, important in sustaining long-term viability of memory T cells 
80. The 
usefulness of IL-7Rα as marker to identify among CD8
+ effector T cells precursors   76
that give rise to long-lived memory cells has already been mentioned (See Section 
1.5.1 and 
36).  
 
In a recent paper, Pantaleo and colleagues have addressed phenotype, function and 
potential life span of TT-specific CD4
+ T cells in healthy subjects who received 
booster TT vaccination 
115. They report that while during the resting state the majority 
of TT-specific CD4
+ T cells have the phenotype of TCM (CD45RA
- CCR7
+), produce 
mainly IL-2 and express high levels of IL-7Rα and BCL-2, upon TT re-immunization, 
however, most of the TT-specific CD4
+ T cells acquire the phenotypic and functional 
characteristics of TEM, down-regulating CCR7 and secreting IFN-γ. Expression of IL-
7Rα and BCL-2 is also down-regulated, but interestingly a fraction of TT-specific 
CD4
+ T cells remain IL-7Rα
high and Bcl-2
high at the peak of the response to TT, and 
the authors speculate that these cells might be the precursors of TT-specific memory 
CD4
+ T cells present later 
115. 
 
In our study on TT vaccination we have partially addressed the point regarding 
functionality of vaccine-induced TT-specific and bystander CD4
+ memory T cells. In 
fact we showed that both could proliferate and produce Th1 and Th2-related cytokines 
upon in vitro re-stimulation with antigen . We used 3H-thymidine incorporation and 
ELISPOT assays to measure proliferation and cytokine production respectively. 
Although ELISPOT method allows analysis of cytokine production at single cell 
level, it does not allow analysis of production of multiple cytokines by the same cell; 
neither allows a phenotypic characterization of cytokine-producing cells. For these 
reasons, we are planning to use multiparameter flow cytometry to study the phenotype 
of TT-specific and vaccine-induced bystander CD4
+ memory T cells and to test their 
ability to produce multiple cytokines. Intracellular expression of the marker Ki67 will 
help identify within the population of antigen-specific CD4
+ T cells, those which were 
actually proliferating in vivo.  
 
A panel of phenotypic markers will be used to characterize the stage of differentiation 
of antigen-specific CD4
+ T cells and their belonging to well characterized subtypes of 
CD4
+ memory T cells.  Among them, expression of the co-stimulatory molecules 
CD27 and CD28, whose loss is associated with late-effector stages of differentiation,   77
will be analysed.  CD45RA in combination with CCR7 will be used to define 
subpopulations of CD4
+ TCM (CD45RA
-CCR7
+), TEM (CD45RA
-CCR7
-), and 
terminally differentiated effectors (CD45RA
+CCR7
-, TET). 
 
To gather information about the potential life span of vaccine-stimulated bystander 
CD4
+ memory T cells as opposed to vaccine-specific CD4
+ memory T cells, two 
markers will be studied: the subunit α of the interleukin 7 receptor (IL-7Rα) and the 
anti-apoptotic molecule Bcl-2.  
 
As a consequence of bystander activation, it could be predicted that quantitative 
and/or qualitative changes in CD4
+ memory T cells may become visible at a 
population level during the TT-induced immune response. In other words, if CD4
+ 
memory T cells are all sensitive to bystander activation during TT recall immune 
response, we should be able to monitor expansion and activation in phenotypically 
defined population or subpopulations of CD4
+ memory T cells in the blood. 
Furthermore, if the phenotype of antigen-specific bystander CD4
+ memory T cells is 
that of TEM cells as it is that of TT-specific CD4
+ memory T cells after TT 
immunization as described by Pantaleo and colleagues 
115(we have to verify this in 
our setting, see above), it might be predicted that changes in the relative proportions 
of TCM and TEM within the CD3
+CD4
+ T lymphocyte population should also become 
visible.  
 
An interesting hypothesis that we also would like to explore is that the recall TT 
vaccination might enhance the basal reactivity of CD4
+ memory T cells by lowering 
the activation threshold required for recall effector functions, such as cytokine 
production. This would offer an additional mechanistic explanation for the increased 
number of bystander cytokine-producing cells that we detected after TT recall 
vaccination. In fact the increased number could result from an in vivo expansion but 
also from a higher number of antigen-specific cells with lower activation threshold for 
cytokine production. It is known that CD4
+ memory T cell display heterogeneity in 
activation threshold for cytokine synthesis. Regulation of activation thresholds can be 
independent of TCR specificity, and signals such as those provided by co-stimulatory 
molecules reduce activation thresholds by lowering the TCR-mediated signals needed   78
to achieve triggering 
116,117. Recently, in a mouse model, the rapid recall effector 
function which characterizes memory as opposed to naïve CD4
+ T cells has been 
associated with an elevated protein expression of the proximal tyrosine kinase Zap 70 
118. The authors propose a “signal threshold model, in which the level of Zap 70 
controls effector responses in CD4
+ T cells, with increased Zap 70 expression leading 
to more efficient cellular responses. In our setting of TT recall vaccination, we are 
planning to investigate basal levels of ZAP 70, but also of other proteins and 
phosphorylated proteins known to play a role in intracellular signaling pathways 
leading to activation of human lymphocytes, in CD4
+ memory T cells and in TCM and 
TEM subpopulations. To our knowledge no study has yet investigated the effect of 
vaccination on the reactivity of CD4
+ memory T cells from this particular angle. 
 
To address all these issues, a new cohort of eleven healthy human volunteers has 
already been recruited. They have received a booster vaccination with TT and their 
PBMNC and sera have been stored for future analysis. 
 
 
1.6.2  Study of bystander activation/proliferation of CD4
+ memory T cells 
following primary hepatitis B immunization 
 
An interesting question is whether bystander activation/proliferation of CD4
+ memory 
T cells can also occur during priming of immune responses. To try to answer this 
question we are planning to analyze vaccine-specific and bystander memory T cell 
responses in healthy human subjects who receive a primary hepatitis B (HepB) 
immunization course. In its standard schedule, this consists of three-doses of vaccine 
(recombinant HepB surface antigen). The first dose (day 0) is followed by a second 
dose after one month and a third dose after six months. Therefore the analysis of 
immune responses in individuals who are receiving the vaccine for the first time, 
offers the unique opportunity to look at bystander activation of Tmem cells (we are 
planning to analyze PPD- and TT-specific CD4
+ T cell responses) while the 
establishment of immune memory against the immunizing antigen is taking place.  
Hep B vaccine is also given to some individuals already immunized against Hep B. In 
this case one dose of vaccine is given to boost pre-existing immunity. These 
individuals would constitute a useful control group in our study.    79
 
In our previous study on healthy subjects who received TT booster vaccination, we 
did not observe bystander antibody production (Figure 1.14), in keeping with a 
previous study after diphtheria vaccination.  These data appear to argue against a 
previously published set of data in subjects vaccinated with TT, where some evidence 
for antigen-independent maintenance of serological memory was seen 
95. Recently 
Odendahl et al. 
92 and Gonzalez-Garcia et al.
93 reported that in normal volunteers 
following TT booster vaccination there is an increase of TT-specific plasma blasts in 
the blood, identified by intracellular staining and flow cytometry analysis using a 
fluorescently-labelled fragment C (FrC) of TT, which peak at day 6 after vaccination. 
Interestingly, they also showed a parallel increase in antibody-secreting plasma cells 
of unidentified (non-TT) specificity. They proposed that these may represent long-
lived plasma cells mobilized from survival niches in bone marrow as a result of 
competition with the newly generated TT-specific plasma blasts. In both papers serum 
antibodies against TT or unrelated antigens were not studied. All together our study 
and these reports show that TT-recall vaccination induces a detectable increase in the 
number of blood plasma cells non TT-specific but does not result in increased levels 
of antibodies with unrelated specificities. So mobilization of resident plasma cells but 
not an increase in number seems to be a correct interpretation.  
 
To further dissect the humoral immune response to vaccination and monitor a possible 
bystander effect in the plasma cell compartment in the setting of hepatitis B 
vaccination, we can take advantage of the fact that most of the recruited healthy 
individuals would be immune to TT.  We can therefore monitor the frequency of TT-
specific blood plasma cells, using the techniques described by Odendahl and 
Gonzalez-Garcia , during the primary and the booster HB vaccination, and relate it to 
the levels of TT-specific antibodies in the serum and to vaccine-specific humoral 
responses. 
 
Ethical approval for this study has been obtained (REC Ref: 06/Q1702/155) and ten 
healthy volunteers have already been recruited. We have started the analysis of the 
immune responses with some encouraging preliminary results.      80
 
2  Chapter 2. Bystander activation of CD4
+ memory T cells: 
further studies using the transgenic OT-II mouse model 
 
 
2.1  Introduction 
 
 
In the study carried out on human healthy volunteers and described in Chapter 1, we 
have evaluated the impact of TT booster vaccination on the functional behaviour of 
populations of human Thmem cells either vaccine-specific or with unrelated antigen 
specificities. The data are indicative of an in vivo bystander expansion of Thmem cells 
specific for unrelated antigens, which occurs possibly as a result of the cytokine-
milieu induced in the lymphoid organs by the ongoing vaccine-specific recall immune 
response.  
 
The techniques used to analyse the kinetics of vaccine-specific and bystander Thmem 
responses, that is the proliferative assay and the ELISPOT assay for cytokine 
production, are both functional assays which require in vitro restimulation of T cells 
with antigen to reveal the presence of antigen-specific T cells. The frequency of 
antigen-specific cells as measured by ELISPOT is generally accepted to closely 
mirror the frequency of those cells in the blood. Although this seems to be the case in 
our study, since we have excluded antigen-induced divisions of cells during the short 
in vitro stimulation period used for the assay, a formal proof of divisions occurring in 
vivo in cells with antigen specificities unrelated to that of the vaccine antigen, is still 
missing. Also the mechanisms responsible for this phenomenon still need to be 
elucidated. Clarifying these issues would require sources of material and 
manipulations which are clearly difficult to obtain in humans.  
 
For this reasons we have decided to develop a mouse model which should help us 
analyze in a more systematic and quantitative way the bystander activation and/or 
proliferation of Thmem cells which follows protein booster vaccination. This is 
achievable by increasing the size of the bystander cell population and its traceability.   81
An obvious choice is that of using CD4
+ T-cell receptor (TCR) transgenic T cells. 
These are isolated from (transgenic) mice in which the rearranged α and β chain 
genes of a single TCR of known specificity are expressed as a transgene, so that the 
majority of mature T cells in the mice will express that TCR. TCR transgenic T cells 
can be activated in vitro or in vivo with a single peptide antigen and they can be 
identified by antibodies specific for the transgenic TCR. 
  
CD4
+ TCR transgenic T cells have been widely used to study generation of CD4 T 
cell memory. A well established protocol involves activation of TCR transgenic T 
cells in vitro and subsequent transfer of these cells into syngeneic, non-transgenic 
recipients 
35. Upon in vitro activation, TCR transgenic T cells acquire the ability of 
surviving for long periods when transferred in vivo, in the absence of re-exposure to 
cognate antigen and without requiring interactions with MHC class II molecules 
68. 
After adoptive transfer, cells also acquire the phenotype (small resting cells , CD25
low, 
CD44
high, IL-7Rα
+) and functional characteristics of ‘bona fide’ CD4
+ memory T cells 
6. In fact, when compared to naïve cells, CD4
+ memory T cell responses to recall 
antigens are characterized by faster kinetics of cytokine secretion, cell division, and 
proliferation which occur at lower doses of antigen and are less dependent on co-
stimulation 
50,51. Furthermore, Löhning at al. have recently shown that long-lived 
functional virus-reactive memory T cells can be generated from purified cytokine-
secreting Th1 and Th2 effectors primed in vitro or in vivo with similar results 
119, 
providing further evidence for the existence, within the population of CD4
+ effector T 
cells (including in vitro-derived effectors), of precursors destined to become memory 
T cells. Interestingly, up-regulation of IL-7Rα, the expression of which is 
instrumental for the survival and homeostatic proliferation of CD4
+ memory T cells 
19,42, occurs very rapidly after adoptive transfer (by day 5) and it correlates positively 
with the number of divisions that the cells had undergone 
119. 
 
For our purposes, we have chosen a well characterized  model of CD4
+ transgenic T 
cells (OT-II) specific for a T helper epitope of ovalbumin (peptide 323-339, OVAp). 
Our initial experimental approach has been to compare the susceptibility to bystander 
proliferation of naïve OT-II to that of antigen-activated OT-II cells. We have labeled 
naïve and antigen-activated OT-II cells with CFSE and then transferred them into   82
wild type C57/B6 mice in which a population of TT-specific CD4
+ memory T cells 
had already been established. Recipient mice were then challenged with TT and 
during the strong recall response against TT, the behavior of the transgenic population 
of OVA-specific memory T cells was monitored (see Figure 2.1). Control 
experiments included the adoptive transfer of naïve and activated OT-II cells into 
naïve recipient mice, as described in more details in Methods. Our results show that 
antigen-activated but not naïve OT-II cells are prone to further activation and 
bystander proliferation when exposed to the particular microenvironment created in 
vivo by an ongoing recall immune response directed against an antigen which is 
unrelated to the one they are specific to. The extent of this OT-II bystander activation 
and proliferation appears proportional to the strength of the secondary immune 
response directed against the unrelated antigen. 
 
2.2  Methods 
 
2.2.1  Antigens 
 
TT, not adsorbed (National Institute for Biological Standards and Control, NIBSC, 
UK). Albumin, chicken egg (ovalbumin, OVA) was purchased by several companies 
and levels of endotoxin were tested by a Limulus Amebocyte Lysate Endochrome-
based assay (Endosafe, Charles River). Ovalbumins from SIGMA (Cat N A 5378-
10G) and from Fluka BioChemika (Cat N 05438) contained very high levels of 
endotoxin and were therefore not used. Ovalbumin from Calbiochem (Cat N 32467) 
contained lower levels of endotoxin which were further reduced to < 0.1 IU/ML by 
two passages through a polimixin B column (Detoxi-Gel, Endotoxin Removing Gel, 
Pierce Cat 20344) according to the manufacturer’s recommended protocol and 
subsequently used for in vivo and in vitro studies. Mouse albumin (MoAlb) also from 
Calbiochem (Cat N 126674), at the concentrations used for in vitro or in vivo assays 
contained ≤ 0.1 IU/ML of endotoxin, and was not further purified. The peptides: p30, 
a universal T-helper epitope from tetanus toxin 
120(tt 947-967, 
FNNFTVSFWLRVPKVSASHLE) and OVAp, a T helper epitope from ovalbumin 
(OVA 323-339, ISQAVHAAHAEINEAGR) were synthesized commercially
 and 
supplied at >95% purity by Peptide Protein Research, Southampton,
 U.K.   83
2.2.2  Mice 
 
C57/BL6 mice were aged between 6 and 10 weeks at the start of all experiments. OT-
II transgenic mice were up to 12 weeks old. Mice were kept in pathogen free 
conditions and in accordance with Home Office Guidelines. Experiments were 
conducted under Project Licence number PPL 70/6401 and Personal Licence PIL 
30/5860. 
 
2.2.3  Generation of TT-specific T cell immunity in CD57/BL6 mice. 
 
To generate TT-specific T cell immunity, C57BL/6 mice were primed sub-
cutaneously (s.c.) in the flank, at day 0 with 50µg of TT in Complete Freund’s 
Adjuvant (CFA). Four weeks later they were boosted with the same amount of protein 
without adjuvant in the same region where the primary injection was delivered. IL-2 
and IFN-γ ELISPOT assays was used to check efficacy of priming and boosting at 
week 2 and 6, respectively. After boosting, mice were left for a period of 8 weeks. 
This period of time is believed to be long enough for T cell memory to be established 
(Prof. Eric Bell, University of Manchester, personal communication). At the end of 
this period, levels of TT-specific T cell responses were checked again and used as 
baseline reference for the final experiment.  
 
2.2.4  IL-2 and IFN-γ ELISPOTs 
 
For IL-2 and IFN-γ ELISPOTs, kits purchased from BD biosciences (IL-2 and IFN-γ 
ELISPOT sets) were used, following the manufacturer’s recommended protocols. 
Spleens were isolated from C57/BL6 mice at weeks 2, 4 and 12 after priming with TT 
and then 1 week after receiving adoptively transferred OT-II cells (Figure 2.1), and 
also from two un-primed naïve mice. Single cell suspensions were obtained by 
passing spleens through a 70µm cell strainer (BD Falcon
TM). Splenocytes were 
subjected to a density gradient centrifugation (Lymphoprep) followed by one wash in 
RPMI 1640 medium (5 minutes at 1600 RPM) before re-suspending them in complete 
medium (RPMI 1640, 1mM sodium pyruvate, 2 mM L-glutamine, non-essential 
amino acids (1X of 100X stock), 50 µM 2-mercaptoethanol, 100 U/mL penicillin, 100   84
µg/mL streptomycin (all from Invitrogen) with 10% heat-inactivated foetal calf-
serum, FCS). 2.5 x 10
5 cells were added to each well of a 96 well ELISPOT plate and 
cultured for 40hours at 37
oC 5% CO2, in triplicates, in the absence (Control) or in the 
presence of TT (20 and 2 µg/ml), MoAlb (100µg/ml), OVA (100µg/ml) and OVAp 
(1µM). Antigen-specific responses were calculated by subtracting the average number 
of spots in Control wells to the number of spots in antigen-stimulated cultures. The 
average number of spots in Control wells was always ≤ 10.  
 
2.2.5  In vitro generation of antigen-activated OT-II T cells 
 
Spleens and lymph nodes (cervical, axillary, inguinal and mesenteric) were isolated 
from naïve OT-II mice and processed as described above (see IL-2 and IFN-γ 
ELISPOTs), with the difference that cell suspensions from lymph nodes were washed 
once in RPMI (5’ at 1600 RPM) without the need for density gradient centrifugation. 
Both cell suspensions were then counted and the number of viable cells was 
determined by Trypan blue exclusion. The percentage of viable cells always exceeded 
95% among splenocytes and 80% among lymph node cells. Viable cells were pooled 
and incubated in complete medium in the presence of 1µM or, in a repeated 
experiment, 0.1µM OVAp. Cells were distributed into 6-well tissue culture plates at 1 
x 10
6 cells/ml , 4-5 ml/well. At day 4, cultures were split 1/2 and 2ml of fresh 
complete medium was added to each well. All this was done very gently in order not 
to disrupt the cell clusters present in high numbers. At day 11 cells were harvested 
and separated by Lymphoprep to remove dead cells and debris. Cells were then 
washed, resuspended in RPMI, counted and labeled with CFSE as described below. 
The phenotype of OT-II cells was checked at day 0 (ex-vivo), day 4 and at day 11 just 
before adoptive transfer (see below 2.2.8 Flow cytometry analysis). 
 
2.2.6  CFSE labeling of OT-II cells 
 
Naïve OT II cells or OT-II cells cultured in vitro with OVAp were washed, 
resuspended in RPMI and counted. The concentration was adjusted to 20 x 10
6 
cells/ml. Carboxyfluorescein diacetate succinimidyl ester (CFSE, Molecular Probes, 
Invitrogen) was added to cell suspensions at a final concentration of 2.5µM, and tubes   85
was transferred into a water bath at 37 
oC. They were mixed occasionally and after 10 
minutes, ice cold FCS was added (1/2 of the initial volume) and tubes were left on ice 
for 5 minutes to quench the reaction. Two washes followed, one with RPMI and the 
second with PBS. After the final wash the number of viable cells was determined by 
Trypan blue exclusion. A small aliquot was used to verify CFSE staining by flow 
cytometry analysis and the remaining cells were used for adoptive transfer 
experiments.   
 
2.2.7  Adoptive transfers of CFSE-labeled OT-II cells 
 
Naïve or antigen-activated OT-II cells were CFSE-labeled and adoptively transferred 
intravenously (i.v.) into the tail vein (1-2 x 10
6 cells in a final volume of 200µL of 
sterile PBS) into either naïve recipient mice or into mice that had been primed and 
boosted with TT. The following day (Day 0) recipient mice were split into three 
groups and received s.c. injections in the flank of either saline, TT or the control 
protein mouse albumin. This control was used to exclude that the simple injection of a 
protein (in this case an autologous protein) could itself induce activation of the OT-II 
cells. A week later, mice were sacrificed. Spleens were isolated and processed (see 
above) and splenocytes were used to study division history and phenotype of 
adoptively transferred OT-II cells by flow cytometry (see below Flow Cytometry 
Analysis) and to quantify endogenous T cell responses against TT by IL-2 and by 
IFN-γ ELISPOTs. This experimental design is summarized in Figure 2.1. A total of 
four different types of adoptive transfer experiments were done as summarized in the 
Table 2.1 below. 
 
Adoptively-transferred cells  C57/BL6 Recipients 
Naïve OT-II  Naïve 
Naïve OT-II  TT-immune 
Antigen-activated OT-II  Naïve 
Antigen-activated OT-II  TT-immune 
 
Table 2.1. Summary of adoptive transfer experiments. 
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Figure 2.1. A transgenic mouse model to study the bystander activation of CD4
+ T cells (see text 
above for a detailed description)  
 
 
2.2.8  Flow cytometry analysis 
 
Phenotypic characterization of OT-II cells was carried out on naïve cells, on cells 
cultured in-vitro with OVAp at day 4 and at day 11 (just before adoptive transfer) and, 
finally, on cells rescued from adoptively transferred recipient mice. In the latter case 
phenotypic analysis was combined with analysis of the cell division history by CFSE. 
Cells were washed in PBS, resuspended in 50-100µl of PBS and stained on ice for 10 
minutes with the appropriate fluorochorome-labeled antibodies as describe below. 
They were then washed once in PBS, fixed with PBS/1% formaldehyde and analysed 
on a FACSCalibur flow cytometry using CELLQUEST software (both from BD 
Biosciences). OT-II cells were identified as being CD4
+ and by the unique 
combination of a T cell receptor (TCR)-V alpha (α) and TCR V beta (β) chain. In fact 
OT-II cells are TCR Vα2
+ and V β5.1, 5.2
+. An example of the gating strategy   87
applied to cells derived from the spleen and lymph nodes of a naïve OT-II transgenic 
mouse is shown below in Figure 2.2. 
 
 
 
Figure 2.2. Gating strategy for the identification of OT-II cells. OT-II cells from splenocyte and 
lymph node cell suspensions were identified as CD4
+ lymphocytes co-expressing TCR-Vβ 5.1, 5.2 and 
TCR-Vα2 chains. 
 
OT-II cells identified in this way were further characterized for surface expression of 
a panel of phenotypic markers which included early and late activation markers and 
lineage markers. Among them: CD25 (PC61) and CD122 (TM-β1) (the subunits α 
and β respectively of the IL-2 receptor), CD127 (SB-199) (the subunit α of the IL-7 
receptor), CD44 (IM7), CD45RB (16A), CD62L (L selectin) (MEL-14) and CD69 
(H1.2F3). CD4 (RM4-5) was conjugated to PerCP, while TCR-Vβ 5.1, 5.2 (MR9-4) 
and TCR Vα 2 (B20.1) were FITC and APC respectively. All the other phenotypic 
markers were PE. All fluorochrome-conjugated antibodies were purchased from BD 
Biosciences, except for CD62L, CD122 and TCR Vα 2, which were purchased from   88
E-Bioscience. OT-II cells rescued from adoptively transferred recipient mice were 
identified among the CD4
+ lymphocytes, as CFSE
+ and TCR-Vα2
+ cells as shown in 
the representative example depicted below (Figure 2.3.A). The proportion of cells 
which had been through one or more divisions was then analysed in details (Figure 
2.3.B) using appropriate gates (M1-M4 in this example) and their phenotype was 
studied using the same combination of markers described above. 
 
 
 
 
Figure 2.3. Gating strategy for the identification of OT-II cells rescued from adoptively-
transferred recipient mice. OT-II cells from splenocytes of adoptively transferred recipient mice were 
identified as CD4
+ CFSE
+ TCR-Vα2
+ lymphocytes. In order to get enough cells for an accurate 
analysis, between 1 and 2 x 10
6 events were collected in the live-lymphocytes gate    89
2.3  Results 
 
Susceptibility of CD4
+ T cells to bystander activation and proliferation was studied 
by adoptively transferring CFSE-labeled CD4
+ transgenic T cells (OT-II) specific for 
OVAp into recipient mice which had been previously primed and boosted with TT, 
and by analyzing their division history and phenotype after inducing a recall immune 
response against TT (see Figure 2.1). In the next two paragraphs the induction of TT-
specific T cell immunity in recipient mice and the generation and 
phenotypic/functional characterization of activated OT-II cells, are described. Finally 
the results from adoptive transfer experiments will be described. From these results it 
emerges that antigen-activated but not naïve OT-II cells are susceptible to bystander 
proliferation which occurs during a secondary immune response directed against the 
unrelated antigen TT.  
 
2.3.1  Generation of a TT-specific T cell memory in mice to be used as recipients 
of adoptively transferred OT-II cells 
 
In order to generate TT-specific immunity in mice which were to be used as recipients 
of OT-II cells in the adoptive transfer experiments, a prime and boost approach was 
used. C56/BL6 mice were primed in the flank with 50µg of TT in CFA and boosted 
four weeks later in the same region with 50µg TT without adjuvant. Levels of TT-
specific T cell immunity were assessed by IL-2 and IFN-γ ELISPOTs two weeks after 
priming and then 2 and 8 weeks after boosting and the results are shown in Figure 2.4. 
Splenocytes were restimulated in vitro for 40h with either optimal or suboptimal 
concentrations of TT (20 and 2 µg/ml) or with p30 (a universal T-helper epitope from 
tetanus toxin). The specificity of cellular immune response was verified by 
restimulating splenocytes with OVA (an antigen which mice had not been primed 
with) and OVAp (a T helper epitope from OVA, which is also the cognate antigen for 
OT-II cells).  
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Figure 2.4. Generation of TT-specific immunity in C57/BL6 mice. In order to induce TT-specific 
immunity, mice were primed subcutaneously with 50µg of TT in complete Freund’s adjuvant (CFA) 
and boosted 4 weeks later with 50µg of TT without adjuvant. T cell responses were checked 2 weeks 
after priming and 2 and 8 weeks after boosting by IL-2 and IFN-γ ELISPOTS following the protocol 
described in Methods (Section 2.2.4). Splenocytes from TT-primed or unprimed naïve control mice 
(2.5 X 10
5 / well, in triplicates) were cultured for 40h in the absence (Control) or in the presence of TT 
(20 and 2 µg/ml), p30 (1µM), OVA (100 and 10 µg/ml) or OVAp (1µM). Antigen-specific responses 
were calculated by subtracting the average number of spots in Control wells to the number of spots in 
antigen-stimulated cultures. The average number of spots in Control wells was always ≤ 10. Cytokine 
responses are reported as the mean number of spots in individual mice and the median value of group 
of mice is indicated by the line across.   91
The prime and boost protocol induced highly specific IL-2 and IFN-γ responses, 
which were still detectable at high levels 8 weeks after the TT boost, suggesting 
effective induction of TT-specific T cell memory.  No cytokine production was 
detected in non-primed naïve mice at any time point (Figure 2.4). 
 
2.3.2  In vitro activation of naïve OT-II cells with cognate peptide: phenotypic 
and functional characterization. 
 
To generate activated OT-II cells, splenocytes and lymph node cells were isolated 
from naïve OT-II mice. Typically between 80 and 90% of the CD4
+ T cells were 
identified as OT-II (TCR Vα2
+ and Vβ5.1, 5.2
+). OT-II cells were cultured in vitro for 
11 days with cognate peptide (OVAp). Flow cytometric analysis was used before 
stimulation and then at day 4 and 11, to study their activation and differentiation 
status. Results of this analysis are shown below in Figure 2.5. In vitro stimulation of 
OT-II cells with OVAp (1µM) resulted in strong cell activation which peaked at day 4 
and was maintained, although to a lower degree, until day 11. In Figure 2.5.A forward 
and side scatter characteristics are shown and a region has been placed on viable 
lymphocytes and their percentage is shown. Cells went through an initial phase of 
expansion, followed by a contraction phase characterized by extensive cell death 
(Figure 2.5.A). At day 4 a large proportion of cells displayed forward and side scatter 
properties (large size and complexity) typical of fully activated and replicating blasts, 
and good viability (78%).  At day 11, cultured cells displayed reduced size and their 
viability was around 35% in this experiment (Figure 2.5.A).   This trend towards a 
reduced viability with longer culture times is one of the reasons for choosing activated 
OT-II cells at this stage of in vitro culture for subsequent adoptive transfer 
experiments (see paragraph 2.3.4). 
 
Figure 2.5.B shows a detailed analysis, focused now on OT-II cells, of side scatter 
characteristics and levels of surface expression of a panel of markers, which includes 
activation and differentiation markers, and cytokine receptors. Among them, we 
analysed expression of CD69 and CD44. CD69 is an early activation marker. CD44 is 
a cell adhesion receptor whose principal ligand, hyaluronate, is a common component 
of extracellular matrices. In the mouse, recently activated and memory T cells express   92
higher levels of CD44 than do naïve T cells 
6. We also analysed CD45RB. CD45 is a 
member of the protein tyrosine phosphatase (PTP) family which comprises signaling 
molecules that regulate a variety of cellular processes including cell growth and 
differentiation 
121. Various isoforms of CD45 exist. In the mouse, the CD45RB 
isoform has been used by some investigators to distinguish naïve T cells 
(CD45RB
high) and memory T cells (CD45RB
low) 
122. Another molecule which was 
included in the panel of phenotypic markers is CD62L or L-selectin, a molecule 
which mediates the binding of T cells to high endothelial venules and therefore serves 
as a homing receptor to lymph nodes, for naïve and some subtypes on memory T 
cells
6. Among the cytokine receptors, expression of CD25, CD122 and CD127 was 
also studied. CD25 is the subunit α of IL-2 receptor (IL-2Rα) and CD122 is the 
subunit β, which is common to IL-2 and IL-15 receptors (IL-2/IL-15Rβ). IL-2Rα and 
IL-2/IL-15Rβ together with the common γ chain (γc), form a high affinity receptor for 
IL-2 
79. IL-2/IL-15Rβ with a unique IL-15Rα and the γc form a high affinity receptor 
for IL-15 
79. Finally CD127 is the specific receptor α chain for IL-7 (IL-7Rα), which 
together with the γc forms the heterodimeric receptor for IL-7 
79. 
 
The phenotype of OT-II cells at day 0 was typical of resting naïve T cells; in fact they 
were CD69
- CD25
-/low CD44
low CD45RB
high CD62L
high. After 4 days in vitro culture 
in the presence of OVAp, the majority of OT-II cells expressed CD69 and, as 
expected, higher levels of CD44 as compared to day 0 naïve cells. CD62L was down-
regulated. Both CD25 and CD122, not expressed on naïve OT-II cells, were strongly 
up-regulated. These phenotypic changes from a CD25
lo CD44
lo CD62L
hi to a CD25
hi 
CD44
hi CD62L
lo phenotype marked the transition from a typical naïve phenotype to 
an effector-like phenotype 
6 (Figure 2.5.B).  
 
At day 11, the percentages of CD69
+, CD25
+ and CD122
+ OT-II cells were reduced 
but still a vast proportion of cells expressed these markers, and CD44 was expressed 
at a level which was intermediate between naïve and fully activated day 4 blasts 
(Figure 2.5.B). Naïve OT-II cells did not express IL-7Rα (CD127). This is difficult to 
explain, given the major role played by IL-7 as survival factor for CD4
+ naïve T cells 
79 and given that expression of CD127 by other CD4
+ TCR transgenic naïve T cells 
with different 
48 or same antigen specificity as the OT-II cells 
43 has been reported.   93
Interestingly CD127 appeared to be up-regulated during in vitro culture, and at day 11 
a minor proportion of OT-II cells expressed CD127 at relatively low level (Figure 
2.5.B).  Overall these results demonstrate that naïve OT-II cells cultured in vitro with 
cognate peptide undergo extensive cell activation which is still maintained when at 
day 11 they are adoptively transferred into recipient mice.     94
 
 
Figure 2.5. Phenotypic characterization of in vitro-activated OT-II cells. Splenocytes and lymph 
node cells from naïve OT-II transgenic mice were cultured for 11 days in vitro in the presence of 1µM 
OVAp. Freshly isolated cells and cells harvested at day 4 and 11 from in vitro cultures, were stained 
with fluorescent-antibodies specific for a panel of phenotypic markers or with their correspondent 
isotype control and analysed on a flow cytometer (see Methods, Section 2.2.8). (A). Forward (FS) and 
side scatter (SC) dot plot illustrating the size (FS) and complexity (SS) of cells. The gate (R1) has been 
drown around live lymphocytes and lymphoblasts and the percentage of gated cells is indicated. (B). 
Size and phenotype of OT-II cells gated as described in Figure 2.2. In each histogram, the percentages 
of positive cells or, where it is more indicated, the mean fluorescence intensity (MFI) are shown for 
day 0 (purple), day 4 (red) and day 11 (green) OT-II cells. Similar results were obtained in a separate 
experiment. 
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2.3.3  Unresponsiveness of OT-II cells activated in vitro with OVAp to in vivo 
priming with cognate antigen (OVA) 
 
OT-II cells which had been activated in vitro with OVAp were further characterized 
and compared to naïve OT-II cells for their ability to respond to cognate antigen in 
vivo after they were adoptively transferred into naïve recipient mice.  Naïve or 
antigen-activated day 11 OT-II cells were CFSE-stained and adoptively transferred 
into C57/Bl6 naïve recipient mice. The following day mice were challenged s.c. with 
either 50µg of OVA or with saline, and a week after, splenocytes were isolated and 
the division history of adoptively transferred OT-II cells was studied by flow 
cytometric analysis as described in Methods. Naïve OT-II cells, as expected, 
responded strongly to the challenge with OVA by proliferating extensively as 
documented by reduced CFSE staining (Figure 2.6). This suggested that in vivo OVA 
antigen was processed and OVAp could be successfully presented to peptide–specific 
OT-II cells. On the contrary, OT-II cells previously activated in vitro with OVAp, 
failed to respond when recipient mice were challenged with OVA. Only a small 
proportion of them had divided at the time of analysis, but similar levels of divisions 
were found also in control mice challenged with saline and they were probably due to 
residual activation and divisions already occurring at time of adoptive transfer.  
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Figure 2.6.  Unresponsiveness of in vitro-activated OT-II cells to in vivo priming with cognate 
antigen. Naive or in vitro-activated OT-II cells were labeled with CFSE and adoptively transferred into 
naïve C57/B6 wild type recipients. Recipient mice were then challenged with 50µg OVA or with 
control saline, and a week later the cell division history of OT-II cells was analyzed by flow cytometry 
using the gating strategy described in Figure 2.3.  
 
 
 
 
 
2.3.4  Bystander proliferation of antigen-activated OT-II during a secondary 
immune response to TT. 
 
After 11 days of in vitro culture with cognate peptide, the susceptibility of OT-II cells 
to bystander activation and proliferation was tested and compared to that of naïve OT-
II cells. The choice of this particular time point (day 11) was dictated by two factors. 
Firstly, to give antigen-activated OT-II cells enough time to start resting and to initiate 
a program of differentiation predicted to lead towards a memory-like phenotype once 
the cells are transferred into recipient mice. Secondly, to enable us rescue enough 
cells from in vitro cultures as viability decreases dramatically over time. 
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Naïve or antigen-activated OT-II cells were adoptively transferred either into naïve 
recipient mice or into mice immune to TT, and the effect of a primary or a booster 
injection of TT on OT-II cells was investigated. Recipient mice were also challenged 
with an autologous protein MoAlb, to exclude the possibility that any observed effect 
on OT-II cells could be due to the injection of a protein itself. This experimental 
design is described in more details in Methods and summarized in Figure 2.1. Here in 
Figure 2.7, the results from the analysis of OT-II divisions by CFSE from four 
representative mice, one from each group of recipient animals, are shown. A 
comprehensive analysis of responses in all animals from all groups is shown in Figure 
2.8. Analysis was done on splenocytes isolated from recipient mice one week after 
they received a s.c. injection of either saline, the control protein MoAlb (50µg) or TT 
(50µg). The gating strategy described in Figure 2.3 was used.  
A clear distinction emerged in the behavior of naïve OT-II cells when compared with 
antigen-activated OT-II cells, with respect to their susceptibility to bystander 
activation and proliferation during an immune response directed against an unrelated 
antigen. In fact the results show that naïve OT-II cells were not sensitive to the 
particular environment created in vivo by either a primary injection of TT (Figure 2.7. 
A), or a booster injection of TT (Figure 2.7.B) and did not divide. A similar result was 
obtained when TT-vaccinated recipient mice where challenged with MoAlb (Figure 
2.7.B). On the contrary, OT-II cells previously activated in vitro with cognate antigen, 
were indeed prone to bystander activation and they divided several times during the 
recall response to TT (Figure 2.7.D, black arrow). This bystander proliferation did not 
occur when recipient mice were challenged with the control autologous protein 
MoAlb, excluding in this way that it could be simply induced by the sub-cutaneous 
injection of a protein (Figure 2.7.D). Also and more importantly, it only occurred 
during a recall response to TT, but not after a primary injection of TT (Figure 2.7.C).  
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Figure 2.7. Bystander activation and proliferation of antigen-activated OT-II TCR transgenic T 
cells during a recall response against TT: representative examples. Naive or antigen-activated OT-
II cells were labeled with CFSE and adoptively transferred either into naïve C57/B6 wild type 
recipients or into recipients which had been previously vaccinated with TT. Recipient mice were then 
challenged with either TT, the control protein MoAlb or saline (see Figure 2.1), and the cell division 
history of OT-II cells was analyzed by flow cytometry using the gating strategy described in Figure 2.3.   
 
 
A detailed analysis of cell divisions of OT-II cells from all mice from the four 
different adoptive transfer experiments is shown in Figure 2.8. In each diagram, the 
percentage of dividing OT-II cells is shown on the Y axis. On the X axis, for mice 
challenged either with saline (S), mouse albumin (MA), TT or with OVA, the 
percentages of OT-II cells which divided once or more than once (≥1), or more 
specifically once (1), twice (2) or three or more than three times (≥3) are indicated. 
The results of the adoptive transfers of naïve OT-II cells into either naïve recipients or 
into TT-immune recipients are illustrated in Figure 2.8.A and Figure 2.8.B 
respectively. As anticipated in Figure 2.7, naïve OT-II cells are not susceptible to 
bystander proliferation and they did not proliferate during a primary (Figure 2.8.A) or 
a secondary (Figure 2.8.B) immune response to TT; however they strongly responded   99
to the challenge with OVA, with extensive proliferation (Figure 2.8.A and B). 
Therefore naïve OT-II maintained fully functionality after adoptive transfer and they 
responded to the cognate antigen which was presented to them upon in vivo 
processing of OVA protein.  
 
The results of the adoptive transfers of antigen-activated OT-II cells into either naïve 
recipients or into TT-immune recipients are shown in Figure 2.8.C and Figure 2.8.D 
respectively. It is clear that OT-II cells primed in vitro with OVAp still show evidence 
of residual activation at the time of adoptive transfer, in fact around 15% and 20% of 
them divided once or more than once during the week after the transfer into naïve or 
TT-immune recipients which were then injected with saline (Figure 2.8.C and D 
respectively). The percentage of OT-II cells that have undergone one or more 
divisions is slightly but not significantly higher than the saline control in naïve 
recipients which were challenged with TT (primary injection) (Figure 2.8.C). The 
most dramatic change in the percentage of antigen-activated OT-II that had undergone 
one or more that one division, as anticipated from Figure 2.7, occurred when TT-
immune recipient mice received a booster injection of TT which induced a strong 
secondary immune response (Figure 2.8.D). In this case an average of 42.3 % of OT-
II cells (33.1-58.9 %) divided once or more than once compared to an average of 
around 20% in the control saline group. Furthermore only in this case OT-II cells 
were found which had undergone three or more divisions. As anticipated this 
bystander proliferation of in vitro-primed OT-II cells was consequence of the 
particular environment created by the on going secondary immune response to TT and 
was not simply due to the injection of a protein as proved by the lack of bystander 
proliferation which followed the injection of MoAlb.  
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Figure 2.8. Bystander activation and proliferation of OT-II TCR transgenic T cells during a 
recall response against TT: summary. Naive or in vitro-activated OT-II cells were labeled with 
CFSE and adoptively transferred either into naïve C57/B6 wild type recipients or into recipients which 
had been previously vaccinated with TT. Recipient mice were then challenged with either TT, the 
control protein MoAlb or saline (see Figure 2.1), and the cell division history of OT-II cells was 
analyzed by flow cytometry using the gating strategy described in Figure 2.3. Results from the four 
different adoptive transfer experiments are show here. In each graph, the percentage of dividing OT-II 
cells is indicated on the Y axis. On the X axis, a detailed analysis of cell divisions is shown for group 
of mice challenge with saline (S), mouse albumin (MA) or tetanus toxoid (TT). Percentages are 
indicated for OT-II cells which divided once or more than once (≥1), or more specifically once (1), 
twice (2) or three or more than three times (≥3). ≥1 = 1 + 2 + ≥3   101
2.3.5  Bystander proliferation of activated OT-II cells in TT-immune recipient 
mice appears to correlate with the levels of endogenous TT-specific T cell 
responses induced by TT booster injection. 
 
 
Some suggestive evidence for a link between the ongoing TT-specific secondary 
immune response in TT-immune recipient mice boosted with TT and the bystander 
proliferation of adoptively transferred OT-II cells was noted.  By measuring the level 
of response to TT in recipient mice, using cytokine-specific ELISPOTs, and then 
assessing the percentages of OT-II cells undergoing one or more cell divisions, it was 
possible to see a correlation (Figure 2.9).  In Figure 2.9.A the percentage of OT-II 
cells undergone one or more divisions after adoptive transfer into TT-immune 
recipients challenged with TT is displayed. In Figure 9B this percentage is shown in 
relation to the percentage of divisions occurring in control recipient mice challenged 
with saline. IL-2 and IFN-γ ELISPOT responses by splenocytes from TT-immune 
mice, recipients of antigen-activated OT-II cells, and isolated one week after 
challenge with TT, are shown Figure 2.9.C.  
 
Splenocytes restimulated in vitro with TT showed strong IL-2 and IFN-γ in vitro 
production, confirming high effector precursor frequency and therefore successful TT 
booster challenge. The proportion of OT-II cells undergone one or more division was 
higher in one of the three recipient mice (TT-1) which showed the highest immune 
response to TT boost, suggesting a correlation between the levels of TT-specific 
cellular responses and the extent of OT-II bystander proliferation. Evidence for a 
correlation was also found in a second independent experiment (see Figure 2.10).   102
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Figure 2.9. The extent of bystander proliferation of antigen-activated OT-II cells appears to  
correlate with the levels of the endogenous TT recall response (measured by IL-2 and IFN-γ 
ELISPOTs) in TT-boosted animals.  
(A) Percentages of activated OT-II cells undergone one or more divisions when adoptively transferred 
into TT-Immune recipient mice which received either a booster injection of TT (TT-1, TT-2 and TT-3) 
or saline (S 1-3, mean and Standard Deviation of S-1, S-2 and S-3).  
(B) Divisions of OT-II cells in TT-boosted mice relative to OT-II divisions in control (S-1-3) mice. 
(C) TT-specific T cell immune responses measured by IL-2 and IFN-γ ELISPOTS in TT-immune mice 
boosted with TT.  
   103
In order to confirm these results, the adoptive transfer of antigen-activated OT-II cells 
into either naïve or TT-immune recipient mice, was repeated in an independent 
experiment. A second aim of this experiment was also to reduce the residual 
activation of OT-II cells at the time of adoptive transfer. In order to do so, a 
possibility was to stimulate OT-II cells in vitro with lower doses of OVAp. OT-II 
cells were stimulated in vitro with 0.1µM OVAp, a concentration which was ten times 
lower than that used in the initial experiment (1µM). The results of this second 
experiment are summarized in Figure 2.10. The use of a ten times lower concentration 
of OVAp to stimulate naïve OT-II in vitro, reduced the residual activation of OT-II 
cells at the time of adoptive transfer, so that only around 10% of them divided more 
than once during their persistence into control recipient hosts (Figure 2.10.A and B: 
Saline, S). As previously observed (Figure 2.8.C), when naïve recipients were 
challenged with TT no bystander proliferation of OT-II cells was evident (Figure 
2.10. A). In contrast, and in line with the results of the previous experiment, when TT-
immune recipients were challenged with a booster dose of TT, the average percentage 
of OT-II cells undergone more than one division doubled reaching an average of 
around 20% (Figure 2.10.B). Furthermore, while virtually no OT-II cell divided twice 
in the control group (saline, S), more than 5% of them divided twice during the 
secondary response to TT (Figure 2.10.B). When the divisions of antigen-activated 
OT-II cells in individual TT-immune recipient mice boosted with TT (Figure 2.10.C 
and D) were correlated to the endogenous TT-specific cellular immune responses 
induced by the booster injection of TT (Figure 2.10.E), again it was found that 
bystander proliferation of OT-II cells was more pronounced in two mice (TT-1 and 
TT-3) which had higher IL-2 and IFN-γ cytokine responses to TT. Overall these 
results mirror those obtained in the previous experiment and support the idea that 
antigen-activated OT-II cells are susceptible to bystander proliferation when exposed 
in vivo to the particular microenvironment created by a secondary immune response to 
an antigen unrelated to the one they are specific to.  
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Figure 2.10. Bystander proliferation of antigen-activated OT-II cells during a secondary immune 
response to TT. Summary of the results obtained in a second independent experiment. 
Analysis of OT-II divisions in: (A) naïve recipients and (B) TT-Immune recipients. (C) Analysis of 
OT-II divisions in individual TT-Immune mice challenged with TT (TT-1, TT-2 and TT-3) or with 
saline (S 1-3, mean and Standard Deviation of S-1, S-2 and S-3). (D) Divisions of OT-II cells in TT-
boosted mice relative to OT-II divisions in control (S 1-3) mice. (E) TT-specific T cell immune 
responses measured by IL-2 and IFN-γ ELISPOTS in TT-immune mice boosted with TT.     105
2.3.6  Phenotype of antigen-activated OT-II cells before and after adoptive 
transfer into TT-immune recipient mice 
 
 
The phenotype of OT-II cells activated in vitro with OVAp was studied at day 0 
(naïve), at day 11 before adoptive transfer (baseline) and then on cells rescued from 
TT-immune recipient mice one week after challenge with either saline, MoAlb or TT. 
Results are shown below in Figure 2.11.A. The phenotype of naïve cells is indicated 
by the dotted purple line and the baseline phenotype is indicated by the solid green 
line. As previously shown in Figure 2.5, also in this experiment, day 11 OT-II cells 
before adoptive transfer still display high expression of activation markers such as 
CD69 and CD44, and CD25 (IL-2Rα). Expression of CD122 (IL-2/IL-15Rβ) on day 
11 OT-II cells, is around 9 %. This value probably under-estimates the real percentage 
of CD122 positive cells as suggested by the significant shift in the fluorescence 
intensity of CD122 as compared with the isotype control (Figure 2.11B). A higher 
expression of CD122 at day 11 would also be consistent with what was previously 
observed during the phenotypic characterization of antigen-activated OT-II (see 
Figure 2.5). In fact in that experiment the percentage of CD122 positive cells reached 
78.1% at day 4 and than decreased, but at day 11 still 34% of OT-II cells expressed 
this marker. Studying co-expression of CD25 and CD122 by the same cell might help 
discriminate the OT-II CD122 positive cells from the negative ones, and it is planned 
for future experiments. 
  
Interestingly, day 11 OT-II cells express CD127 (IL-7Rα) which was not expressed 
by naïve cells. Furthermore they have considerably down-regulated CD45RB which 
was highly expressed on naïve cells (Figure 2.11.A). Overall and in line with what 
was previously found (Figure 2.5), OT-II cells cultured in vitro with cognate peptide, 
before adoptive transfer, show a phenotype which indicate still residual cell activation 
but it also suggests the beginning of a program of differentiation, as indicated by the 
down-regulation of CD45RB and the expression of CD127.  
  
After one week of persistence in recipient control mice (mice challenged with saline), 
a clear down-regulation of activation markers (CD44 and CD69) and of IL-2 receptors 
α (CD25) was visible on OT-II cells. Interestingly CD44 was maintained at levels   106
which were intermediate between the low levels expressed on naïve OT-II cells and 
those expressed on day 11 OT-II cells, and this was accompanied by a parallel further 
up-regulation of IL-7Rα and a further down-regulation of CD45RB (Figure 2.11.A). 
Taken together these changes would suggest that following the initial in vitro 
activation and expansion, OT-II cells adoptively transferred into recipient mice were 
differentiating towards a “resting-like” phenotype with some features typical of 
memory-like cells.  
 
No significant changes in the phenotype of OT-II were detected between the three 
experimental groups, although there was a trend for OT-II cells isolated from TT-
immune recipient mice boosted with TT, to further up-regulate CD44 (Figure 2.11.A. 
Black arrow). This is shown by the same cells which were prone to bystander 
proliferation during the recall response to TT (see Figure 2.8.D). Interestingly, CD44 
expression was the highest (MFI 1088.9) on OT-II cells which had also shown the 
highest bystander proliferation (TT-1 in Figure 2.9.A) and which had been rescued 
from the mouse showing the highest T cell response against TT (TT-1 in Figure 
2.9.C). 
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Figure 2.11. Phenotype of activated OT-II cells before and after adoptive transfer into TT-
immune recipient mice. (A). Phenotype of antigen-activated OT-II cells was studied at day 0 on naïve 
cells (dotted purple line), on cells cultured in vitro with OVAp at day 11 before adoptive transfer 
(baseline, solid green line), and then on OT-II cells rescued from TT-immune recipient mice one week 
after challenge with either saline, mouse albumin (MoAlb) or tetanus toxoid (TT). The method used is 
described in Section 2.2.8 and the gating strategy is illustrated in Figure 2.3. For CD69, CD25, CD122 
and CD127 the percentage of positive cells in relation to the isotype control is indicated. For CD44 and 
CD45RB the mean fluorescence intensity (MFI) is indicated. (B) Expression of CD122 on day 11 OT-
II cells. 
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2.4  Discussion 
 
 
In this chapter we have described the early development of a mouse model aimed at 
studying in more depth the phenomenon of bystander activation of CD4
+ memory T 
cells observed in humans and described in Chapter 1. Our object was to provide 
formal evidence of bystander proliferation of CD4
+ memory T cells occurring in vivo 
during a secondary immune response, and to lay the foundation for addressing the 
possible mechanisms responsible for it in a systematic and quantitative way. 
The initial requirements were therefore:   
1.  Possibility of tracking a particular population of antigen-specific CD4
+ 
(memory) T cells during an immune response directed against an unrelated 
antigen;  
2.  Possibility of quantifying activation status and cell divisions in this population. 
In our experimental approach, we met those requirements by using CD4
+ TCR 
transgenic T cells (OT-II) specific for a given epitope of ovalbumin (OVAp), which 
were available in sufficient numbers and easily traceable thanks to a particular 
combination of fluorochrome-labelled TCR-specific monoclonal antibodies. Once 
identified in this way their activation status could be assessed by a panel of 
phenotypic markers and flow cytometric analysis. CFSE-labelling could provide 
crucial evidence of divisions occurring in vivo. Finally we used an adoptive transfer 
system where CFSE-labelled OT-II cells were transferred into recipient mice in which 
a polyclonal population of TT-specific memory T cells had already been established. 
Therefore when these mice received a booster injection of TT, a strong recall immune 
response was induced. In this context, we initially compared the behaviour of naïve 
OT-II cells to that of OT-II cells activated in vitro with OVAp and then adoptively 
transferred, at day 11, into recipient mice.  
 
It has been shown that, following in vitro activation with cognate antigen and 
subsequent adoptive transfer into wild type recipient mice, CD4
+ TCR transgenic 
naïve T cells differentiate into memory cells and this approach has been widely used 
to study phenotypic, functional and biochemical properties of CD4
+ memory T cells   109
in the mouse 
35,50,51,123. In our hands the in vitro stimulation of naïve OT-II with 
OVAp led to their strong activation and to an initial phase of clonal expansion 
followed by a contraction phase characterized by extensive cell death (Figure 2.5.A). 
The choice of day 11 as the day for the adoptive transfer was therefore justified by the 
necessity of giving cells enough time to rest and at same time to allow us rescue 
enough viable cells to be used in the adoptive transfer experiments. Nevertheless, 
residual activation was still present at day 11, as shown by the phenotypic profile 
(Figure 2.5.B). The phenotype also shows some features, such as the reduced 
expression of CD45RB and the appearance of IL-7Rα which suggests the initiation of 
a process of differentiation predicted to lead towards a memory-like phenotype once 
the cells are transferred into recipient mice. Clearly the lack of response against 
cognate antigen when recipient mice were challenged with ovalbumin (Figure 2.6) 
suggests that these cells, from the functional point of view, were still far from being at 
a memory differentiation stage. They were probably more in need of cytokines to 
sustain their viability after the recent antigen-stimulation.  
  
Bearing in mind that clear differences exist between CD4
+ T cells at a memory 
differentiation stage and the antigen-activated OT-II cells used in the adoptive transfer 
experiments described here, this study has demonstrated a fundamental feature of 
antigen-activated OT-II cells, which characterize them and distinguish them from 
naïve cells. Specifically this is their susceptibility to bystander proliferation which 
occurs during a secondary immune response directed against an antigen unrelated to 
their cognate one (Figures 2.7 and 2.8). The CFSE analysis done after adoptive 
transfer shows that divisions of antigen-activated OT-II cells occurred in vivo, and 
they were clearly linked to the endogenous recall response to TT. In fact they were 
not a consequence of the injection of a protein itself, as demonstrated by the lack of 
division after challenge with the autologous mouse albumin, neither were they present 
after a primary injection of  TT (Figures 2.7 and 2.8). The lack of bystander 
proliferation of antigen-activated OT-II T cells after primary injection with TT, also 
excludes a remote possibility for the bystander proliferation to be a consequence of 
cross-reactivity between the OT-II cognate peptide OVAp, and any possible peptide 
presented to the OT-II cells upon processing of TT in vivo.  
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The mechanisms behind this bystander proliferation still need to be clarified. In 
discussing the study carried out in humans, we pointed to a possible role of cytokines 
secreted during the secondary immune response to TT and to the local 
microenvironment created as a consequence in the lymphoid tissues. Sources of 
cytokines could be the vaccine-specific CD4
+ memory T cells themselves, although 
secretion of cytokine by other immune cells has also to be considered. A cytokine-
driven proliferation is still a possible explanation for the bystander proliferation of 
antigen-activated OT-II cells we reported here. It is supported by the apparent 
correlation between the degree of bystander proliferation of OT-II cells and the 
magnitude of the TT-specific T-cell response.  This was shown by measuring the 
frequency of TT-specific cytokine (IL-2 and IFN-γ)-producing T cells present within 
the splenocyte population isolated from recipient mice after the booster injection of 
TT and comparing this to the bystander activity of adoptively transferred antigen-
activated OT-II cells (Figures 2.9 and 2.10).  
 
If cytokines induced by stimulated TT-specific memory CD4
+ T cells are driving the 
bystander proliferation of antigen-activated OT-II cells, it is still difficult for us at this 
point to come to a definitive conclusion as to which cytokine is involved. Certainly, 
the expression of IL-2 receptors α and β on day 11 antigen-activated OT-II cells 
would render them susceptible to the activity of IL-2 produced in vivo in recipient 
mice during the secondary response to TT. IL-2 is also produced during the priming 
of an immune response, and this is presumably happening during the challenge with 
TT in naïve recipients. In this case the concentrations reached in vivo in the lymphoid 
tissues are probably not high enough for inducing proliferation of adoptively 
transferred antigen-activated OT-II cells. Furthermore it cannot be excluded that at 
day 11, before adoptive transfer, the in vitro-cultured OT-II cells are still producing 
IL-2 and use it in an autocrine loop. If so, this IL-2 is probably sustaining the residual 
proliferation of antigen-activated OT-II cells, which is clearly visible in control mice 
challenged with saline only (Figures 2.8.C and D, 2.10.A and B). However there is no 
reason to believe that the in-vitro activated OT-II cells are induced to produce more 
IL-2 during the TT-specific secondary immune response and that this drives the 
bystander proliferation of OT-II cells.    111
Together with IL-2, other cytokines might also be playing a role in inducing bystander 
proliferation of antigen-activated OT-II cells. Among them IL-7 and IL-15 are good 
candidates, given the role that they play in sustaining long-term maintenance of 
memory T cells 
80. Day 11 antigen-activated OT-II cells express CD122 which is the 
subunit β common to the IL-2 receptor but also to the IL-15 receptor. They also 
express CD127, the subunit α of IL-7R which is not expressed on naïve OT-II 
(Figures 2.5 and 2.11). Overall whether one or more than one of these three cytokines 
has an effect on antigen-activated OT-II cells remains to be proved. In any case a 
putative effect is not accompanied by a further up-regulation of the specific receptor. 
In fact no significant differences were detected between TT-Immune recipient mice 
challenged with saline or MoAlb, and mice challenged with TT in the levels of CD25, 
CD122 and CD127 (Figure 2.11).  Therefore if the bystander proliferation of OT-II 
cells is driven by these cytokines, it can only be explained by the fact that these 
cytokine are present, or their concentration in vivo is sufficiently high, only during the 
TT-specific recall immune response.  Although this might well be the case for IL-2, as 
discussed above, we don’t have any supportive evidence to suggest that during the 
secondary immune response to TT there is a rise in vivo in the levels of IL-7 or IL-15 
above those which might be found in control mice. Getting this evidence might also 
be technically challenging considering that many cytokines have short half-lives and 
do not accumulate to detectable levels as measured in serum samples.  
  
Overall these results are very encouraging, since they reproduce in a defined mouse 
model the observations made in human subjects. They show how OT-II cells activated 
in vitro with cognate antigen and with the capacity to differentiate into memory T 
cells are susceptible in vivo to bystander activation.  Bystander stimulation leads to 
proliferation presumably due to changes in the local micro-environment (cytokine 
milieu), occurring during a recall response directed against an unrelated antigen.  
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2.5  Further investigations 
 
Two aspects of the bystander activation phenomenon require further investigation: 
first the effect of bystander stimulation on “true” memory CD4
+ T cells; second the 
molecular pathway involved in the effect. 
  
To allow full differentiation of antigen-activated OT-II cells into memory cells, we 
are planning to repeat the adoptive transfer experiments of antigen-activated OT-II 
cells into TT-immune recipient mice, but to leave a longer period of time (6-8 weeks) 
between adoptive transfer and induction of the TT recall response. Establishment of 
memory from in vitro-activated precursors will be judged by the phenotype of 
putative memory OT-II cells and by their ability to exert rapid effector functions and 
to proliferate upon re-stimulation with cognate peptide (OVAp). Differentiation of  
antigen-activated OT-II cells into memory cells could take place in an intermediate 
host (if necessary Rag 2
-/-), and in this case after rescuing them, it would still be 
possible to label them with CFSE before the adoptive transfer into the final TT-
immune host, and to study by this means their cell division history. As an alternative 
we could use a congenic system (Thy1.1/Thy 1.2) to discriminate donor and recipient 
cells. To identify proliferating cells within the OT-II population in this setting, we 
could assess DNA incorporation of bromodeoxyuridine (BrdU, an analogue of 
thymidine). BrdU would be administered daily by intraperitoneal injection for the last 
seven days during the TT-specific recall response. 
 
Having established that memory OT-II cells, as well as their antigen-activated 
precursors, are susceptible to bystander activation and proliferation, additional 
questions could be asked. For instance, a crucial issue would be to study the effect of 
repeated TT booster injections, on the long-term persistence of adoptively-transferred 
memory OT-II cells in TT-immune hosts. In other words, if as a consequence of the 
bystander proliferation occurring during secondary immune responses directed against 
unrelated antigens (TT in this case), the lifespan of a population of CD4
+ memory T 
cells (OT-II) is increased, we would have proven in a defined mouse model that our 
speculative hypothesis formulated in the discussion to the study carried out in healthy 
human subjects vaccinated with TT, is fundamentally correct. This would contribute   113
significantly to our understanding of the maintenance of CD4
+ memory T cells with 
important repercussions on the study of natural and vaccine-induced immunity.   114
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